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Introduction: Since the introduction of anti-retroviral therapy (ART), treatment initiation 
criteria have continually been revised to start these lifesaving drugs before onset of advanced 
disease and optimize ART benefits for people living with HIV. However, little is known about 
the effect of these changes on treatment outcomes among young people. We evaluated the 
effect of such a policy change on long term adherence and treatment outcomes among young 
people, aged 15-24 years. 
Methods:  We conducted a retrospective cohort analysis of young people, 15-24years old, 
who started ART from January 2012 – December 2016. We used administrative data from the 
District Health Information System (DHIS2) and the national referral hospital’s EMR. We 
compared young people who started ART in the period July 1st, 2014 to December 31st, 2016 
to a historical cohort that was treated in January 1st, 2012 to 30th June 2014 before the policy 
change. Multivariable logistic regression was used to assess the effect of the 2014 policy 
change on ART adherence and opportunistic infections among those who started treatment 
before and after the guidelines changed. We also run a Cox Proportional Hazards regression 
to examine the effect of the policy change on survival. 
Results: On average, the health facility providing ART and having an opportunistic infection 
at the start of ART, had an effect on ART adherence. The policy change did not have an effect 
on ART adherence. Young people who started ART after the policy change had lesser odds of 
having an OI compared to those who started ART before the policy at 3, 6 and 12 months on 
ART. Age, the health facility, weight, and WHO disease stage were also associated with having 
OIs, as well as duration in pre-ART care, ARV regimen and number of pills per day. There was 
no significant difference in the survival probabilities and the hazard ratios of young people 
who started ART before and those who started ART after the policy changed. Also, WHO 
disease stage, weight at ART start and ART adherence at the time of death had an effect on 
survival. 
Conclusion: This study found that ART adherence among young people was mainly driven by 
differences between health facilities providing ART in Uganda and whether an individual had 
an OI at ART start and not by policy change. Furthermore, early ART initiation reduced the 
risk of OIs among this population. Young people who initiated ART after the policy change 
were less likely to have an OI after starting treatment. Young people were also more likely to 
survive longer after ART initiation regardless of whether they started ART before or after the 
policy change.  
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INTRODUCTION 
Although the current decade has seen an increase in the number of people on life saving 
antiretroviral medication, the Human Immunodeficiency Virus (HIV) continues to be a public 
health threat.  Antiretroviral therapy (ART) has reduced morbidity and mortality among people 
living with virus with more than 11 million lives saved globally in the last decade. Efforts have 
therefore been made to maximize the benefits of antiretroviral therapy (ART) initiation by 
starting treatment as soon as one is diagnosed with the virus, at higher CD4 thresholds and using 
once-a-day fixed-dose combination regimen.  However, the success of ART depends on sustaining 
high levels of ART adherence for viral suppression to stall disease progression.  
In Uganda, a high prevalence rate, an increase in number of children who were perinatally 
infected with HIV becoming adolescents and adults, and an increase in new infections among 
young people, is a growing concern for health professionals and policy makers. Despite increased 
ART coverage, the threat posed by a higher treatment burden, documented poor adherence, 
increasing infections and mortality rates that are not decreasing as in other age groups in this 
population, cannot be overlooked. In addition, little is known about the impact of the changes in 
ART guidelines on ART adherence and treatment outcomes in this population. We therefore 
sought to evaluate the effect of the 2014 ART policy on ART adherence, opportunistic infections, 
and survival among young people, aged 15-24 years and provide information that can be used to 
improve HIV interventions.  
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BACKGROUND 
Uganda has a population of close to 35 million people, 23% of whom are between 18-30 
years and more than 55% are children below 18 years1 . Despite a decline from 18% in the early 
1990s to 7.3% in 2010, Uganda still has a high HIV-related disease burden with a prevalence rate 
of 6.0% for the general population and nearly 4% among adolescents and young adults 15-24 
years1,2 . Findings from the 2016 Uganda Population HIV Impact Assessment reported a gender 
disparity in the HIV prevalence among young people aged 15-24 year with females 
disproportionately affected at 3.3% compared to 0.8% among males2,3. Of the estimated 1.4 
million people living with HIV, only about 30% of eligible adults and 47% of eligible children 
received antiretroviral (ARV) drugs. In 2016, only 27% of adolescents and young adults who were 
eligible for ART were started on treatment3. A recent worrying trend is the rise in new infections 
among this age group, with young women being disproportionately affected. An average of 
22,000 new HIV infections among 15-24-year olds, were reported in 2016 4 of which 68% were 
young women 15-24 years.   AIDS-related mortality is still high and opportunistic infections (OI) 
are still a major cause of death among those whose treatment is not keeping their HIV levels low 
enough for their immune system to fight off infections. All these problems can be linked to 
suboptimal ART adherence as has been widely reported in the literature which increases the risk 
of poor treatment outcomes.  
HIV is an infection that compromises the immune system leaving the infected person 
susceptible to opportunistic infections, leading to high morbidity and mortality. There is no cure 
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for HIV. However, the use of a combination of three or more antiretroviral (ARV) drugs, herein 
referred to as antiretroviral therapy (ART) suppresses the virus from replicating. This suppresses 
disease progression and prolongs the life of the person living with HIV (PLWH). Viral suppression 
is still a challenge given that poor ART adherence still persists among PLWH. 
 
Antiretroviral Treatment Guidelines  
In Uganda ART is implemented under the WHO guidelines that have been disseminated 
since 2002. Revisions have been made over the years as new advances in treatment and new 
data become available. In 2013, WHO provided updated and consolidated guidelines 
recommending earlier ART initiation at a higher CD4 cell count threshold, after findings from 3 
randomized clinical trials and 21 observational studies demonstrated better clinical outcomes for 
patients who started ART earlier compared to those for whom ART was delayed5. Therefore, all 
adults and adolescents started ART at CD4 cell count ≤ 500cells/mm3, using a more efficacious 
first line regimen with less life-threatening side effects. Priority was given to those with advanced 
disease or with CD4 cell count ≤ 350cells/mm3. A 2nd edition of the consolidated guidelines was 
disseminated in 2016 but for this study the focus is on the 2013 ART guidelines (implemented in 
Uganda in July 2014) because we believe that information has implications for the latest 
guidelines.  
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Healthcare System and HIV service provision 
In Uganda, the majority of healthcare is provided by the government through a tiered 
system comprising of the National Referral Hospitals (NRH), Regional referral hospitals (RRH), 
General hospitals, lower-level health centers (Level IV- Level II) and village health teams (VHT). 
The RRHs are located in each of the 14 health zones that cover the four geographical regions of 
the country, within 5 kilometers of the majority of the population.  These provide the bulk of HIV 
treatment services in the country. HIV care and treatment though provided at all levels of the 
healthcare delivery system, most of the financial support is from international donors like the 
Centers for Diseases Control and Prevention (CDC), The Joint United Nations Programme on HIV 
and AIDS (UNAIDS), and The United States Agency for International Development (USAID). These 
work in collaboration with the Ministry of Health, national implementing partners like Baylor-
Uganda and the existing health facilities.   
 
HIV Treatment and Follow-up  
Patients who are diagnosed with HIV are referred to the HIV clinic for care and treatment. 
Those who are eligible for ART receive at least 3 counselling sessions, in accordance with the 
national treatment guidelines to prepare them to start ART which is a lifelong commitment. The 
first follow-up visit is scheduled 2 weeks after ART initiation to monitor response to the 
prescribed regimen including drug toxicity and side-effects. Thereafter monthly visits are 
scheduled. Patients that are stable are given longer (usually 2 months) appointment times, which 
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is unusual for adolescents and young adults because of their challenges with adherence. The 
clinic visits are scheduled to coincide with the ARV drugs refills. During each visit, patients 
undergo a comprehensive clinical assessment that includes a physical examination and virological 
testing as described in the national guidelines. The parameters assessed included ARV drug 
regimen and adherence to medication; potential side effects; weight and height; TB status and 
presence of other OIs; loss of function; clinical disease stage; laboratory investigations and 
whether the patient had been hospitalized since the last clinic visit. CD4 count tests are done 
every six months and viral load testing is done 6 months after initiating treatment and annually 
thereafter. Patient records are routinely updated at every clinic visit including those that are lost-
to-follow-up (LTFU), transferred in from other clinics/out to other clinics, or have died. Most 
deaths are reported by relatives, community health workers and volunteers. Since there is no 
death registry, for this study, we used the recorded date of death in the medical record.   
 
Antiretroviral Therapy before and after July 2014 
Prior to July 2014, ART initiation was recommended for PLWH with a CD4 cell count ≤350 
cells/mm3 or with advanced disease stage 3 or 4 as defined in the World Health Organization 
Clinical staging guidelines. This is referred to as “delayed ART” because the patient started ART 
at a certain level of disease severity (WHO guidelines). A patient with a higher CD4 count was 
more likely to be Stage I or II and was considered to be healthy and therefore did not need ART. 
However, a patient with a lower CD4 count was more likely to be Stage III and IV and therefore 
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needed ART to stop the disease progression. In resource-limited settings where CD4 testing was 
not widely available, clinical disease stage was the criteria used to initiate ART. Also, before 2014, 
priority for ART was given to children <5 years, pregnant women and very sick PLWH. Therefore, 
during this period, many young people did not start ART if they did not meet the eligibility criteria. 
Their ART was delayed in this context. Patients with WHO clinical stage I or II were given 
cotrimoxazole prophylaxis to reduce the risk of opportunistic infections and given medication for 
any other problems they had. All patients were assessed physically and immunologically on a 
monthly basis for signs of disease progression. In July 2014, Uganda adopted and implemented 
the 2013 WHO ART guidelines which recommended that ART be initiated for PLWH at CD4 cell 
count ≤500 cells/mm3, referred to as “early ART initiation” because a higher CD4 count is 
indicative of a healthier person. This led to more PLWH started ART before getting to the 
advanced disease stages.  
ART initiation in both time periods (pre- and post-July 2014) was administered using one 
non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside reverse transcriptase 
inhibitors (NRTIs), as first line therapy. The NNRTIs included Efavirenz (EFV) or Nevirapine (NVP). 
The NRTIs were Zidovudine (AZT), Tenofovir (TDF), Lamivudine (3TC) or Emtricitabine (FTC). 
However, whereas pre-July 2014 the patients could be started on either AZT or TDF, post-July 
2014 all patients had to be started on a TDF-based regimen, with Efavirenz (EFV) as the preferred 
option for the NNRTI. The ARV drugs are administered as a triple fixed dose combination, for 
example, TDF/3TC/EFV or as duo fixed dose e.g. TDF/3TC used with another separate ARV such 
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as EFV or NVP. The choice of regimen was guided by the patient’s clinical condition, availability 
of drugs and presence of a contra-indication to any of the available drug options. 
  
Study Sites  
The research study was conducted in four tertiary level hospitals; one national and three 
regional referral hospitals, selected for their geographical representation.  Each of these hospitals 
has a specialized HIV clinic for young people that is open all week days. Patients routinely receive 
a package of services that includes adherence assessment and support education and counseling, 
and clinical and laboratory monitoring for disease progression and opportunistic infections. A 
peer model in which young people are trained to identify fellow young people with adherence 
challenges and support them is used to foster adherence.  Patients with poor adherence are each 
initiated on an intensive adherence counselling plan and followed up till they reach satisfactory 
levels before being reintegrated into routine clinical routines.  Across all the four sites, ART and 
other forms of HIV treatment is free of charge with a centrally procurement and distribution 
system run by government warehouses. With the exception of the national referral hospital that 
has a computerized physician order entry system, regional referral hospital operates a paper 
based clinical notes system in which clinical findings and treatment procedures are summarized 
on a patient card during each follow up visit. These cards are kept at the health facility and later 
entered an EMR data base (District health information system [DHIS2]) for analysis and reporting.  
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Baylor College of Medicine Children’s Foundation-Uganda (Baylor-Uganda) 
Baylor-Uganda is located in Mulago National Referral Hospital in the central region, and 
also serves as a teaching hospital for medical professionals. An affiliate of the Baylor International 
Pediatric AIDS Initiative (BIPAI)’s network of clinics, Baylor-Uganda is the largest pediatric HIV 
clinic in Uganda and Africa that provides comprehensive HIV care and treatment services for 
children and adolescents infected with HIV/AIDS. The clinic has been in existence since 2003 and 
has an estimated daily attendance of about 200 patients with a total enrollment of 7000 patients. 
Over 1800 patients aged 15-24 years have been started on ART since 2011.  
Fort Portal Regional Referral Hospital 
The Fort Portal Regional Referral Hospital, located in Western Uganda, serves close to 
500,000 people in the Rwenzori Region. The HIV clinic, founded in 2002 has a total enrollment of 
nearly 8000 patients in care with about 7000 started on ART between 2011 to date. 
Mbale Regional Referral Hospital 
The Mbale Regional Referral Hospital is located in Eastern Uganda. A cumulative total of 
about 6400 adults and children are currently receiving ART at the hospital’s HIV clinic. Of these 
400 adolescents and young adults have started ART since 2011.  
Gulu Regional Referral Hospital 
The Gulu Regional Referral Hospital, located in the northern region, offers comprehensive 
HIV services to the Acholi sub-region. Over 6000 patients with HIV infection are receiving ART at 
the HIV clinic, 786 of whom are adolescents and young adults.   
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STATEMENT OF THE PROBLEM  
Although HIV infections have reduced tremendously in the last few decades, Uganda still 
has a high HIV-related disease burden with a prevalence rate of nearly 4% for young people, 15-
24 years3 . The number of children who were prenatally infected with HIV, who are surviving into 
adulthood is increasing. The rise in new infections and AIDS-related deaths among this age group 
is also a source of concern among health professionals and policy makers. The initiation of ART 
at a higher CD4 count threshold herein referred to as “Early ART”, using more efficacious ARVs 
and a lower pill burden, it is believed will greatly reduce the number of infections and deaths3-8. 
However, the success of ART relies on sustaining high levels of ART adherence for viral 
suppression9,10, which is a problem in this age group. 
 Early ART initiation also raises medication adherence concerns in a population that has 
been widely reported to have poor adherence11-15. The threat of poor adherence in this age group 
cannot be overlooked given that ART adherence rates are lower, mortality rates are not 
decreasing as in other age groups and there is a rise in new infections8,16. Between 2005 and 
2012, the number of deaths among this age group increased by 50% whereas overall it had 
decreased by 30% 6. In Uganda, a total of 5200 AIDS-related deaths were reported among young 
people 15-24 years in 20164. The risk of drug resistance is increasing and this has implications on 
viral suppression. Young people are staying on treatment longer than adults leading to a higher 
treatment burden, it is therefore important to examine the implications of these policy changes 
on treatment outcomes.  
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Furthermore, most published literature focusses on children and adults, is mostly from 
high income countries, with this age-group aggregated as either children or adults, and therefore 
excluded in most of the statistical data analyses. More studies with better age disaggregation are 
needed.  
Although a few studies have examined the effect of treatment guidelines in sub-Saharan 
Africa and Uganda, their main focus was drug efficacy, reducing morbidity and mortality. None 
of these studies have assessed the effect of the changing ART guidelines on adherence and 
treatment outcomes in this age group and the implications on future HIV programs. Therefore, 
in this study, we sought to assess the effect of changes in ART guidelines on ART adherence, 
opportunistic infections and survival among young people in Uganda, 15-24 years, who initiated 
ART before and after the implementation of the 2013 ART guidelines.  
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LITERATURE REVIEW  
A considerable amount of literature has been published on treatment outcomes since the 
outbreak of the HIV epidemic. However, the limitations of current studies on adolescents and 
young adults, not limited to study designs, study populations, and mixed results underpinned the 
importance of this study. The benefits of ART on outcomes for people infected with HIV cannot 
be over emphasized and a substantial amount of literature has been published about it.  
However, only a few studies have been done in resource-limited settings like Uganda. There is 
even more paucity of information when it comes to adolescents and young adults. 
A substantial amount of literature available for Sub-Saharan Africa is based on pre-2010 
ART treatment guidelines that recommended ART initiation at a lower CD4 count threshold 
(<200cells/mm3) and the available ARVs were less efficacious than those currently available. ART 
initiation is currently recommended at a higher CD4 count threshold (≤ 500cells/mm3), using 
more potent ART regimens5,7. For this study, we sought to understand how newer (2013) 
guidelines impacted treatment outcomes in Uganda. We analyzed data from adolescents and 
young adults over time and believe that the results can be used to inform policy and improve 
effectiveness of ART among this population.  
Early initiation of ART is associated with reduced mortality and morbidity caused by the 
HIV infection. Montaner et al. (2014) who sought to characterize the association of HAART with 
new AIDS cases and mortality, reported an 80% reduction in both AIDS incidence (from 6.9 to 1.4 
per 100,000 population) and HIV-related mortality (from 6.5 to 1.3 per 100,000 population)8. 
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Positive results have also been reported elsewhere. A multi-country study of 30 countries with 
the highest AIDS mortality burden found that access to ART averted about 1,051,354 and 422,448 
deaths in South Africa and Nigeria and increasing coverage could avert 2.2 and 1.2 million deaths 
respectively 9,10. 
 
ART among Adolescents and Young Adults 
Considerable evidence shows that successful treatment of perinatally infected children, in 
addition to managing opportunistic infections and increasing ART coverage has led to an increase 
in the number of HIV-infected adolescents and young adults on ART17,18 . Nachega et al. (2009) 
argued however, that despite the number of large studies that described virological outcomes of 
ART in adults and children, very few looked at adolescents and young adults per se. For example, 
the START Trial11 that assessed the clinical outcomes of immediate versus delayed ART initiation 
did not include adolescents.  
Adolescents are at risk of poor health outcomes and acquisition of new HIV infections as a 
result of poor use of ART. Mutevedzi and Newell (2014) reported a large number of new HIV 
infections showing up among adolescents and young adults. Data from the Global Health 
Observatory Data Repository supports this finding. Furthermore, adolescents have poor 
adherence rates compared to adults and children12. 
“Over one third (38%) of adolescents globally are sub-optimally adherent to ART, with 
substantial regional variation”13 . 
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“HIV infected adolescents and young adults on ART in Southern Africa have poor 
adherence rates and poor virologic outcomes than their adult counterparts”14. 
A review by Lowenthal et al. (2014) of the changing epidemiology of HIV among 
perinatally-infected adolescents in Sub-Saharan Africa also revealed increased risk of chronic lung 
disease, cardiac disease, skin, renal and bone disease. They also noted that growth failure was 
more pronounced during adolescence. All this affected adherence to treatment, education and 
the overall quality of life.  They further argued that existing studies were cross-sectional in nature, 
had small sample sizes and lacked controls against which comparisons could be made. On the 
other hand, studies from high income settings lacked age-specific data. These mentioned 
limitations made generalizability of the results to HIV-infected adolescents and young adults in 
Uganda a challenge.  
Ford, Mills and Egger (2014) in their editorial commentary argued that the meta-analyses 
such as the one done by Siedner et al. (2015), were prone to ecological biases because of the use 
of aggregated data. Similar studies like Ferrand et al. (2016) scored the quality of many of the 
studies used in their systematic review as low or moderate. They could not make accurate 
estimates about the effectiveness of ART on viral suppression because there was a lot of variation 
in the number of adolescents achieving viral suppression in the studies they reviewed.  They also 
found that many of the studies did not stratify by duration of ART and none included age-specific 
analysis both of which were associated with treatment adherence. This was a gap that this study 
hoped to address.  
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It should also be noted that before 2010, only children 0-5 years were started on ART if 
they tested positive for HIV. Older children, adolescents and adults, started ART only if they had 
advanced disease, defined by the WHO as clinical disease stage III and IV or having a CD4 cell 
count below a recommended threshold. Therefore, newly diagnosed adolescents and young 
adults may not have been eligible for ART and thus were excluded from most studies. According 
to UNAIDS, in 2013 there were 200,000 young people (15-24 years) out of 1.2million PLWHA in 
Uganda. Of these 41% adults (15+years) were started on treatment. The number of young people 
15-24 years is not disaggregated. This study sought to capture more of them and provide results 
that are more generalizable.   
 
Adherence to ART  
Early ART does not only have implications on costs, service delivery and access to care, but 
also on adherence. As earlier mentioned, long-term medication adherence is a challenge for any 
disease and HIV is not an exception. Added to this is the frequently required clinic visits which is 
still the case in Uganda as in many other Sub-Saharan African countries.  Recent studies15,16 in 
the US that underscored the importance of timely and uninterrupted care, also reported a high 
rate of missed clinic visits during the first year in HIV care. Furthermore, social and psychological 
factors, adverse side effects, drug toxicities, pill burden, daily doses and drug interactions are 
documented barriers to ART adherence. Although the current ARV drugs are more potent and 
effective17, they still have minor adverse effects that PLWHA have to deal with.  
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Medication adherence is a major determinant of ART success. Several studies 13,18,19  found 
that non-adherence to ART treatment led to drug resistance, increased viral load, disease 
progression, decreased CD4 cell count and death.  It was also argued that not all PLWHA took 
their medication as prescribed. Different approaches such as clinician documented prescription 
refills, directly observed therapy, self-report and microelectromechanical systems (MEMS) 
technology have been used to address this problem.  However, non-adherence remains a major 
threat to the success of ART. 
A meta-analysis by Stricker et al. (2014) found that on average 62% of patients reported ≥ 
90% adherence. These findings are similar to those reported in an earlier study by Mills et al. 
(2006)20. However, a retrospective study done in Nigeria19 that analyzed medication refill 
adherence found that refill adherence reduced with successive visits. This means that fatigue set 
in, which in turn affected adherence overtime.  Even with the single once-daily fixed dose 
regimen that has reduced the pill burden tremendously, Gulick (2010)21 found that only 60-80% 
of patients achieved complete viral suppression. 
Concerning adolescents and young adults many study findings pointed to their poor 
adherence compared to children and adults.  Findings from a systematic review by Kim, Gerver, 
Fidler and Ward (2014) found that almost 40% of adolescents who were eligible for or started 
ART were non-adherent to treatment. Nevertheless, they also noted that the studies in that 
analysis looked at the period before the CD4 count threshold for ART initiation was raised, the 
ART regimens were less potent and had unpleasant side effects. Therefore, analyses that are 
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more recent were needed to assess adherence among this population. They also noted 
considerable variation in the studies that were included in the review most of which were cross-
sectional because the paucity of longitudinal studies. Also, countries like the United States, Brazil 
and South Africa were over-represented. Existing data is therefore incomplete and the 
magnitude of the problem of non-adherence is not really known. It is also likely that the incidence 
of medication non-adherence is actually higher than published. The methodological difficulties 
associated with measuring adherence may therefore be underestimating the extent of the 
problem. 
In Uganda adherence is measured using pill counts and self-reports. At each clinic visit, the 
patient is asked to return with all medicine containers from the previous visit and a pill count is 
done and recorded in the patient HIV care/ART card. This card is a record of all patient 
information, including all follow-up visits and is kept at the health facility/clinic. Clinic visit 
reminders, and other information is recorded in the patient’s book that acts as a copy of the 
patient’s medical record that the patient has access to. However, research has shown that pill 
counts and self-reports are subjective and may be over reporting adherence and underestimating 
the problem of non-adherence. This may be associated with the increase in AIDS-related 
mortality, likelihood of OIs and new HIV infections among this population. 
Furthermore, many factors affect adherence in this age group. Social and psychological 
factors22, treatment fatigue12, stigma and size of tablets23, education24 and transitioning from 
pediatric care to adultcare25, and non-disclosure20 have been documented in published 
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literature.  The association between age and adherence has already been established. Adherence 
is reported to decline with age among adolescents and young adults26. The Pediatric AIDS Clinical 
Trial Group (PACTG 219C) found 76% adherence rates for ages 15-18 years compared to 83-89% 
in younger children26. Mekuria L.A et al. (2017), Auld et al. 2014 and Nachega et al. (2009) also 
found significant associations between age and suboptimal adherence.  
We cannot overemphasize the need for more evidence-based literature. Most of the 
literature on ART adherence among adolescents and young adults is from high-income countries. 
The meta-analysis by Mills et al. (2006) that is cited in most literature did not include adolescent 
populations from Africa. Furthermore, very few longitudinal studies have been done in Sub-
Saharan Africa. One longitudinal study done by Sasaki et al. (2012) in Zambia focused on a rural-
based population sample using pre-2010 ART treatment guidelines. Current analyses, like this 
study, are therefore needed to assess factors associated with ART adherence and allow for more 
generalizable results.   
 
Opportunistic infections (OI)  
OIs are still a major threat to PLWHAs as they increase the risk of morbidity and mortality19-
22 . They negatively affect the quality of life and threaten the success of ART treatment. Findings 
from Rubaihayo et al. (2016) showed that OIs increased stigma, affected a patient’s response to 
treatment and led to increased healthcare costs since the affected patient had to visit the health 
facility more frequently.  
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ART reduces the load of HIV in an infected person’s body enhancing the person’s ability to 
fight off OIs and live longer. A large cohort study by Guillen et al. (2010) reported that ART 
initiation led to a reduction in incidence and prevalence of OIs among children in high-income 
countries. In 2016, a systematic review by Drouin et al. (2016) focused on low- and middle-
income countries (LMIC), found similar results except for bacterial pneumonia, tuberculosis (TB), 
and candidiasis. They however noted that many of the studies lacked lost-to- follow-up data that 
was key in incidence studies. They also lacked data on confounders such as CD4 cell count, age 
at ART initiation and use of cotrimoxazole prophylaxis, a key medication used to prevent OIs. 
Poor adherence, a major determinant of treatment failure increases the risk for OIs27. 
Iroezindu and colleagues (2013) examined the OI prevalence and risk factors in patients on ART. 
They found that 22.4% had OIs despite reported good adherence rates among 78% of study 
participants. The study may have under- or over-estimated some infections because it lacked 
diagnostic test data.    
Although the evidence supporting the success of ART in significantly reducing OIs and AIDS 
progression cannot be disputed, differences still exist in the burden of OIs between high-income 
countries (HIC) and LMIC settings. Prevalence and incidence rates also vary between and within 
countries - 22.4% was reported by one study in Nigeria28, 30% in Senegal29, and 47.6% in South 
Africa30. Studies done in Ethiopia31 and West Africa32 had similar findings. The endemicity of 
diseases such as tuberculosis and pneumonia in some areas may have influenced study findings. 
However, different CD4 count thresholds were used in each of these studies and that variation 
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should be accounted for when using the results. A systematic review by Low et al. (2014) that 
reviewed studies from Sub-Saharan Africa, Asia, Latin America and the Caribbean noted a 57% - 
91% decline in risk of oral candidiasis, toxoplasmosis and Pneumocystis pneumonia (PCP), during 
the first year on ART. They still found a significant number of PLWHA presenting with advanced 
disease, an issue that cannot be overlooked in face all the achievements made by ART. However, 
they also noted that there was a lot of variability in study parameters such as reporting 
cotrimoxazole prophylaxis, ART regimens, and duration on ART, follow-up times and lack of 
information on important confounders like CD4 cell count. 
As earlier noted, adolescents and young adults have been understudied. Most of the 
literature focuses on adults and children. According to Shroufi et al. (2013), many research 
programs put little emphasis on adolescents and young adults and concentrated more on infants 
and younger children. With reported poor adherence to ART, the risk of OIs among this subgroup 
is increased but it is not documented. An observational cohort study by Nachega et al. (2009) 
found that lower virologic suppression and immunologic recovery was common among 
adolescents and young adults because of poor ART adherence. This increases the risk of 
infections. 
A few of the studies done in Uganda focused on children ≤ 15 years but with more 
emphasis on infants. Others focused on adults 18 years and above. Literature on adolescents and 
young adults is very limited. A prospective cohort study by Namutebi, Kamya and Byakika-Kibwika 
(2013) focused on the age group 28-40 years and found that though OIs had declined, they should 
20 
 
not be ignored because patients still present with advanced disease.   Rubaihayo et al. (2016) 
assessed OIs before and after ART initiation and found that OIs accounted for 91% of all 
opportunistic events, the most common being diarrhea < I month and geohelminths. They also 
found that oral candidiasis was still present although not as highly prevalent as in previous years. 
These studies, however, used different study designs, had adults as their study population, and 
some lacked data on confounders like patient’s CD4 counts, duration on ART and reported ART 
adherence. 
It was therefore important to obtain updated analyses on the impact of ART on OIs, ever 
since the global scale-up of ART coverage and use of more potent ART regimens. Existing 
literature such as Holmes et al. (2003), Nachega et al (2009), and Hull, Phillips and Montaner 
(2008) preceded this period and/or addressed specific OIs and regions. Low et al. (2014) also 
argued that country-specific evidence-based assessment of prevalent OIs would help define local 
priorities and inform targeted expenditure on and procurement of relevant prophylaxis drugs, in 
addition to treatment of HIV-related comorbidities. 
This longitudinal study sought to provide updated information by exploring the magnitude 
of OIs among young people in Uganda and identify the risk factors associated with them. 
 
Survival and Predictors of Survival  
The use of ART has been associated with improved survival among PLWH. It is one of the 
indicators, though difficult to measure, that is used to evaluate program performance.  One of 
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the causes of death among PLWH is the presence of OIs.  Patients with advanced HIV disease 
have a higher risk of OIs when initiated on ART, which in turn increases their risk of death. Results 
from a South African study showed that OIs and the Immune Reconstitution Inflammatory 
Syndrome (IRIS) were major causes of death after initiation of ART33. IRIS is a combination of 
clinical signs and symptoms considered to be associated with immune recovery brought about 
by a response to ART. It occurs among 10–30% of the people initiating ART, usually within the 
first 4–8 weeks after initiating therapy. 
Furthermore, patients with poor adherence have a higher risk of death because of poorly 
controlled viral load. Ayele, Mulugeta, Desta and Rabito (2015) found that the risk of death was 
nearly 3 times higher (HR: 2.9695, 95% CI: 1.396 – 5.203) among patients with poor adherence 
compared to those with good adherence. A similar study in Ethiopia by Hambisa, Ali and Dessie 
(2013) found that non-adherent patients were 27 (95% CI: 8.928, 86.8) times more likely to die 
than adherent patients were. However, the confidence interval was wide. A Ugandan study34 
reported that non-adherent patients were 2 times more likely to die compared to adherent 
patients. But as noted with many studies, the study by Hambisa et al. (2013) had a lot of missing 
data on OIs, an important determinant of mortality used in several studies.  
According to the WHO and UNAIDS, adherence to ART is critical to the survival of PLWHA 
since poor adherence was the main reason for poor treatment outcomes35.Early initiation of ART 
improves survival of PLWHA7,23,24  and reduces the cost of healthcare. Cost-effectiveness studies 
such as Bendavid, Grant, Talbot, Owens and Zolopa (2011) found that a TDF regimen was 
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associated with highest survival (135.2 months of quality adjusted life expectancy), and fewer 
opportunistic infections 36. 
Despite the benefits of ART in improving survival, patients still die when started on ART 
although the numbers as not as high as they used to be. The number of patients that died in the 
first year of ART was estimated to be between 8% - 26%37. Most of the deaths occurred in the 
first few months of ART. This may change as more updated analyses based on newer ART 
guidelines recommending earlier ART initiation at a higher CD4 count threshold and with more 
potent ARVs, become available.  Amanzi, Michelo, Simoonga, Dambe and Chongwe (2016) 
reported low survival rates during the first year on ART, similar to findings from Tanzania38 and 
Cameroun39. A patient with a lower CD4 count (≤200 cells/mm3) had a lower chance of survival 
compared to one with a higher CD4 count (≤350 cells/mm3) at the start of ART. The median 
survival found in a 5-year Tanzanian cohort was 24 months40. This was lower than was reported 
in an earlier Tanzanian cohort by Johannessen et al. (2008) and in Uganda34. The Cameroun 
study39 also found patient characteristics, adherence and quality of healthcare were independent 
predictors of survival.  
A 2015 retrospective cohort study done in Ethiopia found that 12.2% of the patients died 
during 5 years of follow-up, 68% of whom died in the first 6 months of ART initiation41.  Mageda, 
Leyna and Mmbaga (2012) found that mortality was 4.3 per 100-person years with more deaths 
happening within the first 5 months following ART initiation. The authors noted however, that 
most patients had CD4 cell count less than 200 cells/mm3. This variability could be explained by 
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the different time-periods, wide variation in age-range and different study designs, in addition to 
the low CD4 count. It should also be noted that highly active antiretroviral therapy (HAART) was 
not readily available in many African countries before 2012. Therefore, current analyses will 
significantly contribute to the body of knowledge since they are based on a higher CD4 cell count 
and more potent ARVs that are now available.  
One can also argue that although Nachega et al. 2009 is one of the very few published 
studies reporting adolescent clinical outcomes in Africa, the causes of mortality among 
adolescents and young people was not well documented. This supports the argument that 
adolescents and young adults living with HIV have been understudied and yet available literature 
highlights their risk of poor health outcomes. This study sought to add to available research by 
providing adolescent and young adult-specific data that can be used to improve HIV interventions 
in this population.   
 
Patient Factors  
Uganda scaled up efforts to increase ART coverage countrywide in 2012 and with the 
reported success, it is easy to overlook what is happening over time. Studies also demonstrate 
that ART alone is not a sole determinant of mortality.  
A patient’s use of healthcare services is a function of predisposing, enabling, and need 
factors as demonstrated by the Andersen Behavioral Model. A substantial amount of studies 
found associations between these factors and ART use. Greer et al. (2015) examined the 
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association between new HIV patients and IOM treatment indicators and found that poverty was 
associated with poor adherence to ART and poor clinic appointment attendance. Age was also 
found to be significantly associated with ART use26.  
Furthermore, if patients are not ready to start ART, treatment initiation would be delayed, 
which in turn increased the risk of transmission, disease progression and even death. This is a 
serious concern for both patients and health providers. Many of the patients perceive ART as a 
death sentence25,26 . Therefore, preparation and assessment of the patient’s readiness has to be 
taken into consideration too.  
This study sought to provide a deeper understanding of factors, specific to Uganda, that 
affect adherence to HAART among adolescents and young people living with HIV, to better 
develop interventions to improve adherence in this population and reduce barriers to HIV care 
and treatment. 
 
 
 
 
 
 
 
25 
 
PUBLIC HEALTH SIGNIFICANCE 
The importance of documenting what happens to adolescents and young adults in order 
to design interventions that will effectively improve HIV treatment outcomes cannot be 
overlooked. The HIV epidemiology has changed and coupled with new antiretroviral treatments 
and treatment indications, there is need for more timely data. This study provides country-
specific evidence-based assessment on occurrence of opportunistic infections, ART adherence 
and survival among adolescents and young adults. This information can be used to identify 
priority areas in HIV service provision and improve treatment outcomes especially as the country 
seeks to implement the latest guidelines aimed at further reducing the time between HIV 
diagnosis and ART initiation.  This longitudinal analysis also provides policy makers with a deeper 
understanding of factors that are associated with early initiation of ART in this population. This 
information can then be used to target expenditure on, and the procurement of relevant 
prophylaxis drugs, in addition to treatment of HIV-related comorbidities.  Furthermore, this study 
will contribute to the growing body of research5, and in addition to ongoing trials to evaluate the 
impact of early ART initiation, barriers and drivers of adherence, and incidence of adverse events 
from increased exposure to ART. This study therefore provides updated information that can be 
used to improve ART adherence and treatment outcomes among young people in Uganda and 
thereby reduce barriers to HIV care and treatment. 
26 
 
THE CONCEPTUAL FRAMEWORK  
The conceptual framework that underpinned this study is a modified version using 
features from both the Donabedian Structure-Process-Outcome (SPO) model42,43  and the 
Anderson Behavioral model (ABM)44, underpinned by the HIV Care Continuum45,46. The SPO 
model illustrates the relationship between structure, process and outcome of the healthcare 
system, the ABM model incorporates the patient characteristics influencing that relationship.  
The HIV Care Continuum (HCC) illustrates the stages of care a person living with HIV goes 
through from diagnosis to viral suppression. It is used globally to track the number of PLWH at 
each stage and identify priority areas to improve HIV delivery services. The stages, important in 
the fight against HIV, involve having adequate care provision conditions and resources to provide 
that care. On the other hand, however, the success of HIV care is also dependent on the patient’s 
right and willingness to accept or defer treatment5. This is influenced by a number of factors 
illustrated by the ABM model in the literature as predisposing, enabling and need factors. This 
study focused on the predisposing factors of age and sex27,28, and examined their association with 
the study outcomes. In the Donabedian model, structure is defined as “the conditions under 
which care is provided, including material resources, human resources, and organizational 
characteristics”42. In order to provide quality HIV treatment, adequate physical and human 
resources have to be available. For this study we operationalized structure as type of health 
facility, its location and patient volume. These were broadly defined since the detailed aspects 
are not the focus of this study. The process of providing HIV care includes ART treatment routine 
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clinic visits, drug refills and viral load monitoring, among other activities.  Donabedian defined 
these as the “set of activities that constitute health care, including diagnosis, treatment, 
rehabilitation, prevention and patient education usually carried out by professional personnel”42. 
If the process is not working well, then the outcomes would not be desirable. This study 
operationalized the process as early initiation of ART for PLWH at CD4 cell count ≤500cells/mm3 
as recommended in the 2013 WHO guidelines. We examined the association between early ART 
initiation and study outcomes; (i) adherence to ART medication, (ii) occurrence of OIs and (iii) 
survival, among adolescents and young adults living with HIV in Uganda. These outcomes were 
defined to as “changes (desirable or undesirable) in individuals and populations that can be 
attributed to health care”42.  Figure 1 shows the modified model that guided this study. It 
illustrates the relationship between the different components of this study.    
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Figure 1: Conceptual Framework 
THE HIV CONTINUUM OF CARE
Patient Characteristics 
- Age, Sex
(Covariates)
 Improved Adherence to 
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Opportunistic Infections
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Adapted from Donabedian 2003 and Kane 1997; Andersen 1995 (Source: Begley et al 2008; 
Glanz 2008; R.M Andersen 1995) and modified by the Researcher 
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Hypothesis, Research Question and Specific Aims  
Research Question  
What is the effect of the changes in the WHO 2013 ART guidelines, herein referred to as early 
ART initiation and adopted in Uganda in 2014, on treatment outcomes among young people living 
with HIV in Uganda?  
Overall Aim 
The broad aim of this study was to assess the impact of changes in ART policies on patient 
outcomes, over time, among young people living with HIV, 15 - 24 years of age, in high-volume 
health facilities in Uganda. We hypothesized that young people who started ART after the policy 
changes were implemented would have better treatment outcomes compared to those who 
started ART before the policy changed. 
Specific Aims 
Aim 1: To assess the effect of changes in ART guidelines on ART adherence among young people 
15 - 24 years, before and after the ART policy change.  
 Hypothesis: We hypothesized that young people would have better ART adherence after 
the policy change.    
Aim 2: To assess the effect of changes in ART guidelines on Opportunistic Infections (OI) among 
young people 15 - 24 years, before and after the ART policy change.  
 Hypothesis: We hypothesized that there would be fewer OIs among young people who 
initiated ART after the policy changed compared to those who initiated ART before. 
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Aim 3: To assess the effect of changes in ART guidelines on survival and identify predictors of 
survival among Young people 15 - 24 years, the ART policy change. 
Hypothesis: We hypothesized that young people who initiated ART after the policy 
changed would have a lower risk of death compared to those who initiated ART before 
the policy change. 
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METHODS 
Study Design and Data source 
We conducted a retrospective cohort study comparing young people who started ART in 
the period July 1st, 2014 to December 31st, 2016 to a historical cohort that was treated in January 
1st, 2012 to 30th June 2014 before the policy change. We used administrative data from the 
District Health Information System (DHIS2) and the national referral hospital’s EMR. This data, 
routinely collected from patients who receive HIV treatment at the health facilities during clinic 
visits, is used to plan and track a patient’s treatment from the date of HIV diagnosis to the date 
he/she leaves the clinic either through transfer-out to another clinic, lost to follow-up (LTFU) or 
death.  
For this study design we needed patient information over a period of time, which 
information was not readily available in most health facilities.  This study was conducted in four 
tertiary level hospitals; one national and three regional referral hospitals, selected for their 
geographical representation.  These hospitals have a high patient volume, have electronic 
medical records that covered the study period and therefore, provided an adequate sample 
population. These health facilities were also at the forefront of implementing the new ART 
guidelines before scale-up of services to lower-level health facilities. 
Electronic Medical Records (EMR) 
We used de-identified secondary data that was routinely collected from patients that 
received HIV treatment and recorded in the EMR. The Baylor-Uganda EMR was developed by 
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BIPAI in 2005 to manage real time registration, appointments and enhance tracking of patients. 
It is used in all BIPAI-affiliated COEs in more than 10 different countries worldwide.  
The Regional Referral Hospitals (RRHs) started using EMRs in 2011 using an open source 
medical records system platform, OpenMRS which was developed for use in developing 
countries. The OpenMRS system, a collaboration between the Regenstrief Institute, a world-
renowned medical informatics research institute, and Partners in Health a Boston-based 
organization, focused on health service delivery for the underprivileged worldwide. This was later 
revised and a newer platform, the District health information system [DHIS2]) was adopted at 
the national level for reporting and analysis.  The databases contain information on patient 
demographics and clinical parameters, not limited to: date of diagnosis, ART initiation date, CD4 
cell count, adherence, and presence/absence of OIs, stage of disease; registration date; and 
status of the patient. 
These databases were appropriate for this longitudinal study design because of the ability 
to track a patient from the time of registration in the clinic, course of treatment, up till the time 
they exited the clinic due to death, transferred-out to other clinics or are lost-to-follow-up. It was 
therefore possible to follow-up the study participants over the study period. 
Study Cohort  
We defined the study population as young people aged 15-24 years. The study included 
all HIV-infected young people, 15-24 years at the time of ART initiation, who started ART between 
January 1, 2012 and December 31, 2016, regardless of the date of HIV diagnosis. We included 
those who were newly diagnosed with HIV and those who were diagnosed prior to the study 
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period but had not started ART. The cohort entry point was the date of ART initiation with each 
study participant contributing follow-up time to the study period. Young people had to have data 
for at least two follow-up visits, had to have started ART at the selected HIV clinics, and be on 
lifelong ART. Young people who were LTFU or transfer-out during the study period were included 
because they contributed time until the event happened.  However, we excluded young people 
who were lost- to- follow-up at the start of study period; started ART for Pre-exposure 
prophylaxis (PrEP) because it is short term; had no records; and had started ART elsewhere 
because the data from the original health facility was not readily available. The study cohort was 
closed on December 31, 2017 to ensure that all study subjects had data for at least two follow-
up visits.  
For all the study participants that met the selection criteria, we extracted their pre-ART 
data. The patient information included socio-demographic characteristics, date of ART initiation, 
CD4 cell count, WHO clinical disease stage, cotrimoxazole prophylaxis, ARV regimen, number of 
ARV pills given per day and ARV refills, among other patient data that was relevant to the study.  
 
Sampling Frame 
The sampling frame used for this study was the Pre-ART and ART registers in which all 
patients diagnosed with HIV and received treatment at the selected health facilities are 
registered.  The registers contain both baseline and follow-up information about each patient 
and are updated at every clinic visit.  
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Sample Size  
The selection of study participants was not based on probability sampling. We included 
all patients that met the inclusion criteria in the analysis. However, we performed a power 
analysis to obtain an adequate number of subjects to detect a difference and be able to answer 
our research question. Literature on effect sizes used in HIV treatment outcomes research in 
Uganda is very limited and mixed.  However, a randomized clinical trial47 and case-control study48 
conducted in Kenya used 10% effect size, the smallest difference that would be of clinical 
importance in the HIV field. Results from meta-analyses (mean weighted ES) range from 0.10 – 
0.7949,50,50,50,50,50,50,50,50,50,50,50,50. The total number of adolescents and young adults who were 
included in the analysis was 3084. This gave the study 80% power to detect an effect size of 0.08 
based on a two-sided t-test at 0.05 significance level, assuming that the outcome variable at 
baseline was continuous and normally distributed. 
 
Study Variables  
Dependent Variables:  
ART Adherence: The dependent variable “ART adherence” was defined as the percent 
adherence for each patient during the first 12 months of starting ART.  This was coded as a binary 
variable, “1” if the patient had an adherence code corresponding to ≥95% adherence and “0” 
otherwise. An adherence rate of ≥95% is the threshold necessary for sustained clinical 
effectiveness of ART9,29,30.  A young person was considered to be adherent if he/she had a code 
of “1” for all the months at 3, 6 and 12 months of follow-up. An individual was considered to be 
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less adherent if he/she had a code of “0” for any of the months at 3, 6 and 12 months of follow-
up. 
Opportunistic Infections (OI): We defined the dependent variable “opportunistic 
infection” as a disease event diagnosed during a clinic visit and recorded in the patient’s medical 
record as an OI. The ART clinics use the WHO classification of OIs5,31. This was coded as a binary 
variable, “1” if the patient had an OI and “0” otherwise. A young person was considered to have 
an OI if he/she had a code of “1” for any of the months at 3, 6 and 12 months of follow-up. An 
individual who had an OI at 3 months, was considered to have an OI at 6 and 12 months.  
Survival:  We defined survival as the time between ART initiation and death or end of 
study period. For more comparable results the total follow-up time for each group was restricted 
to 36 months after starting ART. For young people in the pre-policy group, the censor date was 
December 2014 and for those in the post-policy group, the censor date was June 2017. Length of 
time was measured in months. The variable was coded as “1” if the patient died and “0” 
otherwise.  
 
Independent Variables:  
Policy change group (pre/post): The independent variable of interest was a binary time 
variable representing the before and after introduction of the guidelines (pre-policy=0, post-
policy=1). The pre-policy group included young people who started ART before July 2014 (January 
2012 – June 2014) and the post-policy group included young people who started ART after July 
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2014 (July 2014-December 2016).  The ART start date was the date the patient was given a dose 
of ARVs.  
 
Socio-demographic variables 
Age: Age is a key predictor of ART adherence. ART Adherence has been reported to 
decline with age among young people32. 
Gender: Studies have reported that females are more likely to be adherent to ART 
compared to males. Females are disproportionately affected by HIV in this age group.  
Health facility/ART clinic: The clinic providing the HIV treatment is important to this 
analysis because of the geographical representation and the differences in structure and clinical 
processes.  
 
Clinical Characteristics 
Weight: The weight of the patient is documented at each clinic visit so that any weight 
loss in a short time is immediately addressed. Extreme weight loss is indicative of treatment 
failure. 
WHO clinical disease stage (coded as I, II, III and IV): The WHO clinical disease stage (I-IV) 
is an indicator of disease severity and in the absence of CD4 testing and more recently viral load 
testing, clinical stage was used as the eligibility criteria to assess for ART initiation. 
CD4 count at ART start: CD4 count is a key indicator for both disease severity and 
virological failure. It was commonly used during the study period to assess eligibility for ART. The 
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change in ART policy raised the CD4 count threshold increasing the number of young people 
starting ART. 
Treatment Characteristics 
Duration in pre-ART care (coded as 0, 1) 
Pre-ART care is the time between a positive HIV diagnosis and ART initiation. This duration defers 
from patient to patient depending on the health professional’s assessment of the patient’s 
readiness to start ART and availability of drugs among other factors. One of the changes in the 
guidelines has been the reduction of the pre-ART period. 
ARV Drug regimen (coded as 0, 1)  
This variable captured the ARV drug given to the patient at the start of ART. The regimen is not 
changed unless the patient shows signs immunological or virological failure. Prior to 2014 a 
patient could be started on either an AZT-based or a TDF-based regimen as first line. After 2014, 
for all patients TDF was the first line regimen. It should be noted that those that were doing well 
on other regimens prior to the change, were not switched to the new regimen. Among the ARV 
regimens are TDF-3TC-EFV, TDF-FTC-EFV, TDF-3TC-NVP, TDF-FTC-NVP, AZT-3TC-EFV, AZT-3TC-
NVP, AZT-3TC-ATV, ABC-3TC-ATV, ABC-3TC-EFV, and other combinations. 
Number of ARV pills per day (coded as 0, 1) 
We derived the number of ARV pills per day given at ART start by dividing the number of ARV 
pills given by the total number of days the pills were given. 
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Cotrimoxazole Prophylaxis (coded as 0, 1) 
Cotrimoxazole prophylaxis is given to all HIV positives patients irrespective of whether they 
started ART or not. This is a key medication for treatment of many bacterial infections that plague 
PLWH.  
Table 1 below is a summary of the all variables and definitions that were used in this study.  
Table 1: Measurement Matrix of the Study Variables 
Measured Variable Aim Definition 
Dependent Variables 
ART Adherence  Aim 1 Binary Outcome: 1= Adherent, 0=Less adherent 
Opportunistic Infections  Aim 2 Binary category: 1 =” had an OI”, 0= otherwise”  
Survival time to death Aim 3 
Time from ART initiation to death/end of study 
period  
Independent Variables 
Demographic characteristics 
Policy change group All  Binary category: 1=Post-Policy, 0=Pre- policy 
Year of ART Initiation 2 
Categorical variable: 1=20 12, 2=2013, 3=2014, 4 
=2015, 5=2016 
Health facility All  
Categorical variable: 1=ART Clinic 1, 2= ART Clinic 
2, 3= ART Clinic 3, 4 = ART Clinic 4 
Age  All  Binary category: 1 =15-19, 0=20-24 
Sex All  Binary category: 1 =Female, 0=Male  
Clinical Characteristics 
Weight All Continuous:  weight at ART initiation (in kgs) 
Had an OI at ART start 2,3 Binary category: 1= had an OI, 0=otherwise 
WHO Disease Stage*  All 
Categorical variable: 1 = Stage I, 2 = Stage II, 3 
=Stage III & IV 
Treatment Characteristics 
Duration in pre-ART care All  Binary variable: 0=<1 month, 1=1 month or more 
ARV regimen All  Binary variable: 1= TDF-based, 0=Non-TDF,  
ARV Pills Per Day 1 Binary variable: 1 = 1 pill, 0 =2 pills or more 
Cotrimoxazole prophylaxis  1,2 Binary variable: 1= Yes CTX, 0 = otherwise 
*This classification is based on the World Health Organization (WHO) clinical staging 
criteria 
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Data Supervision and Management  
The dissertation committee provided the overall supervision and management of the 
study. The researcher supervised the data extraction exercise with the help of data specialists in 
health records and staff from the participating health facilities. The data was de-identified by 
generating new study IDs that were used in the analysis for all participants to ensure privacy and 
confidentiality of the patients’ information. The patient clinic IDs were only used in the data 
cleaning process and quality checks. The data was cleaned using STATA 15.1 and re-coded by the 
researcher and a trained data manager, to create an analysis file. The abstracted data was 
encrypted and stored on a password-protected computer of the researcher. The back-up dataset 
was password-protected too and stored on the UTSPH server in Houston. All study records will 
be disposed of as required, using the records disposal policies of Baylor-Uganda, Ministry of 
Health - Uganda and UTSPH. 
 
Data Collection  
We extracted existing patient-level data from the electronic medical records databases of 
the selected health facilities into a Microsoft Excel spreadsheet. The starting point of the data 
extraction was the date the patient started ART. For those entered into the study cohort, we also 
extracted their Pre-ART data.  The data extraction was done by a trained Health Information 
Technologist, using a data extraction tool (Appendix 1) and guided by the variables described in 
the measurement matrix. For quality assurance, we did a reliability check using a random 
selection of the patient charts.  Figure 2 illustrates how the data was extracted. 
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Figure 2: Data Extraction Plan  
Adolescents and Young Adults who 
started ART 
(N=3532)
AYA who met the study criteria
(N=3084)
Started ART between 
Jan 1, 2012 – June 30, 2014
(N=1545)
Started ART between 
July 1, 2014  – Dec 31, 2016
(N=1539)
• Started ART after 12/31/2016
• Had no follow on visit
• Transfer-ins
• Referred from the ward
(N=448)
Study Aims
The effect of early ART on Opportunistic 
Infections (OIs)
The effect of early ART on Survival 
The effect of early ART on 
Adherence Aim 2
Aim 3
Aim 1
 
 
Data for 3532 young people was extracted from the databases of one national and three regional 
referral hospitals. Out of these, 448 young people did not meet the inclusion criteria and were 
therefore excluded from the analysis. We extracted data on patient clinical information including 
sex, age, CD4 cell count, WHO disease stage, ARV regimens, ARV pills given per day, 
cotrimoxazole prophylaxis, and dates of clinic visits. Data on death, LTFU and transfer-outs was 
also extracted, in addition to data on ART adherence and opportunistic infections recorded 
during the follow-up clinic visits. 
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Data Analysis 
 All statistical analyses were performed using STATA 15.1 (StataCorp LP, College Station, 
TX, USA) and SAS 9.4 (SAS Institute Inc, Cary, NC, USA). We described patient baseline 
characteristics using frequencies and percentages for categorical variables, and means and 
standard deviation, for continuous variables.  These were compared using T-tests and Pearson’s 
chi-squared tests, respectively. All p-values were two-tailed and considered statistically 
significant at α=0.05. To assess associations of each independent variable with the dependent 
variables, univariable analyses were first performed. We conducted multivariable logistic 
regression analyses to determine the effect of the change in policy on the study outcomes, 
controlling for the independent variables at the start of ART. All variables that were statistically 
significant at p-value <0.25 or had prior clinical significance for the outcomes from the univariable 
analysis, were included in a multivariable regression model. We checked the correlation between 
the variables to ensure that none was highly correlated. Possible interactions were also checked. 
The variables that were included in each of the regression models are described under each aim.  
 
Aim 1: The effect of ART guideline changes on antiretroviral adherence  
All the young people who met the selection criteria were included in this analysis. We 
defined the dependent variable “ART adherence” as the percent adherence for each patient 
during the first 12 months of starting ART.  This was coded as a binary variable, “1” if the patient 
had an adherence code corresponding to ≥95% adherence and “0” otherwise. An adherence rate 
of ≥95% is the threshold necessary for sustained clinical effectiveness of ART9,29,30.  A young 
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person was considered to be adherent if he/she had a code of “1” for all the months at 3, 6 and 
12 months of follow-up. An individual was considered to be less adherent if he/she had a code of 
“0” for any of the months at 3, 6 and 12 months of follow-up 
The independent variable of interest was a binary time variable representing the before 
and after introduction of the guidelines (pre-policy=0, post-policy=1). The pre-policy group 
included young people who started ART before July 2014 (January 2012 – June 2014) and the 
post-policy group included young people who started ART after July 2014 (July 2014-December 
2016).  The patient socio-demographic characteristics included in the regression model were 
gender, age at ART initiation and health facility providing treatment.  The clinical characteristics 
were weight, OI at ART start (Yes, No) and WHO clinical disease stage (I, II, III &IV) at ART start. 
The treatment characteristics included duration in pre-ART care (less than 1 month, 1 month or 
more), ARV drug regimen (TDF, Non-TDF), the number of ARV pills per day (1 pill, 2 pills or more) 
given at ART start, cotrimoxazole prophylaxis at ART start (Yes, No). 
We used a multivariable Logistic regression model to examine the association between 
the changes of the ART guidelines and ART adherence.  We adjusted the model for the 
independent variables described above.  The variables were assessed at both univariable and 
bivariable levels to see which factors were associated with the study outcome before fitting them 
to the final multivariable model, using a p-value of <0.25 and clinical relevance.  Possible 
interactions or effect modifiers were also assessed. The underlying assumptions of regression 
models were checked. 
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Aim 2: The effect of ART guidelines changes on opportunistic infections 
All the young people who met the selection criteria were included in this analysis. 
The dependent variable was a disease event diagnosed during a follow-up clinic visit and 
recorded in the patient’s medical record as an opportunistic infection (OI). This was coded as “1” 
if the patient had an OI during the months after starting ART and “0” if the patient did not have 
an OI during the months after starting ART. A young person was considered to have an OI if 
he/she had a code of “1” for any of the months at 3, 6 and 12 months of follow-up. An individual 
who had an OI at 3 months, was also considered to have an OI at 6 and 12 months. 
The independent variable of interest was a binary time variable representing before and 
after the introduction of the guidelines (pre-2014 policy =0, post-2014 policy=1). The pre-policy 
group included young people who started ART before July 2014 (January 2012 – June 2014) and 
the post-policy group included young people who started ART after July 2014 (July 2014-
December 2016). We adjusted the regression model for socio-demographic characteristics (age 
at ART start, gender and ART clinic), The clinical characteristics were weight, OI at ART start (Yes, 
No) and WHO clinical disease stage (I, II, III &IV) at ART start. The treatment characteristics 
included duration in pre-ART care (less than 1 month, 1 month or more), ARV drug regimen (TDF, 
Non-TDF), the number of ARV pills per day (1 pill, 2 pills or more) given at ART start, cotrimoxazole 
prophylaxis at ART start (Yes, No) and ART adherence  (adherent, less adherent) at 3, 6 and 12 
months on ART. 
We fit a multivariable Logistic regression model to examine the association between the 
changes in the ART guidelines and occurrence of opportunistic infections.  We adjusted the model 
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for the independent variables described above. We run three separate models at 3 months, 6 
months and 12 months to see if early initiation of ART was successful in keeping the infections 
low. The variables were assessed at both univariable and bivariable levels to see which factors 
were associated with the study outcome before fitting them to the final multivariable model, 
using a p-value of <0.25 and clinical relevance.  Possible interactions or effect modifiers were also 
assessed. The underlying assumptions of regression models were checked. 
 
Aim 3: To assess the effect of ART guidelines changes of survival and identify predictors of 
Survival  
Survival was defined as the time between ART initiation and death if it happened before 
the end of the study period for each group.  Young people who were LTFU, transferred out or 
were alive at the end of the study period were censored.  We restricted the follow up period to 
36 months after starting ART for each cohort so as to have comparable results. For young people 
who started ART before the guidelines changed, the censor date was December 2014 and for 
those that started ART after the guidelines changed, the censor date was June 2016. The variable 
was coded as “1” if the patient died and “0” otherwise.  The independent variable of interest was 
a time dummy variable representing the pre-and post-policy periods.  We adjusted the regression 
model for socio-demographic characteristics (age at the time of death & Gender), clinical 
characteristics (weight, OI at ART start (Yes, No) and WHO clinical disease stage (I, II, III &IV) at 
ART start) and treatment characteristics (duration in pre-ART care (less than 1 month, 1 month 
or more), ARV drug regimen (TDF, Non-TDF), the number of ARV pills per day (1 pill, 2 pills or 
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more) given at ART start, cotrimoxazole prophylaxis at ART start (Yes, No). We tested the 
difference in survival functions of both groups using the log-rank test. We fit a Cox Proportional 
Hazards regression model to assess the association between ART policy changes and survival, 
adjusted for the independent variables above. We generated time-to-event data, in months, 
based on the date of death or end of study.  Current age was derived from adding the duration 
in ART care to the age at ART start and used it as a time-varying variable. The variables were 
selected using a p-value of <0.25 and clinical relevance.  We checked the underlying model 
assumptions of the proportional hazards model using the model-based test for time by log (t) 
interaction.  
Human Subjects Considerations  
Informed Consent/Assent was waived for this study because there was no contact with 
or direct participation of patients. A waiver of consent was obtained for the charts reviewed for 
quality assurance. Each study participant was assigned a de-identified unique number that was 
used for analysis. The study was approved by the Makerere University School of Public Health, 
Uganda National Council of Science and Technology, Baylor College of Medicine’s Institutional 
Review Board, and Committee for the Protection of Human Subjects at the University of Texas 
Health Sciences Center at Houston.  
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JOURNAL ARTICLE 1 
Effect of Antiretroviral Therapy Policy Change on ART Adherence among Young People living 
with HIV in Uganda. 
Abstract  
Objectives: Although changes in treatment policy has led to initiation of antiretroviral therapy 
(ART) before onset of advanced disease resulting in better treatment outcomes, it has 
implications on long term adherence among young people. We evaluated the effect of such a 
policy change on ART adherence among young people, aged 15-24 years in Uganda. 
Methods: This retrospective analysis of young people living with HIV, 15-24years old, who started 
ART from January 2012 – December 2016 used administrative data from the District Health 
Information System (DHIS2) and the national referral hospital’s EMR. Multivariable logistic 
regression was used to assess the effect of the changes in policy on ART adherence among those 
who started treatment before and after the guidelines changed. 
Results: ART adherence was affected by the health facility providing ART and having an 
opportunistic infection at the start of ART. The policy change did not have an effect on ART 
adherence. Although the percentage of adherent young people decreased at 3, 6 and 12 months, 
it increased for the less adherent young people. 
Conclusion: This study found that ART adherence among young people was mainly driven by 
differences between health facilities providing ART and having an OI at ART start.  ART adherence 
declined over time. Therefore, whereas initiating treatment before onset of advanced disease is 
beneficial, the implications on long term adherence cannot be overlooked.   
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Introduction  
The current decade has seen an exponential increase in the number of people on life 
saving anti-retroviral medication1,3,33. The WHO estimates that ART has saved 11.4 million lives 
worldwide over the last decade34. Despite these achievements, Uganda still has a high HIV-
related disease burden with a prevalence rate of nearly 4% among young people 15-24 years3. 
There is also an increasing number of children who were prenatally infected with HIV, surviving 
into adulthood17. A rise in new infections and AIDS-related deaths among this age group became 
a concern among health professionals and policy makers. Within this context there were efforts 
to maximize ART for HIV treatment and improve patient outcomes by revising policies to initiate 
ART early in the course of the illness. With initiation at a higher CD4 count threshold, ART can 
prevent the majority of these infections and deaths given the evidence it has greatly reduced 
morbidity and mortality among HIV-infected individuals3-8.  However, the success of ART relies 
on sustaining high levels of ART adherence for viral suppression9,10.  
Although high income countries adopted the “test and treat strategy” as early as the year 
2000, low- and middle-income countries (LMICs) used a more gradual approach due to cost 
implications and projected demands on already weak healthcare systems. Uganda adopted the 
2013 ART guidelines in July 2014 and started initiating ART for all young people at CD4 cell count 
≤500 cells/mm3, using a once-a day fixed-dose combination regimen. Despite increased ART 
coverage, the threat posed by a higher treatment burden cannot be overlooked15, 20,31,49,50.  This 
also raises medication adherence concerns in a population that has been widely reported to have 
poor adherence11-15. This age group has lower ART adherence rates, mortality rates are not 
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decreasing as in other age groups and there is a rise in new infections8,16. Furthermore, knowing 
that early initiation means that young people are staying on ART longer than adults, it is 
important to examine the implications of these policy changes on their adherence.  
Few studies have examined ART adherence among young people in sub-Saharan Africa 
and Uganda15,35-37. However, none of them have assessed the effect of the changes in ART policy 
on adherence in this age group and the implications on future HIV programs. We therefore 
assessed the effect of such a policy change on ART adherence. 
 
Methods 
Study Design and Data source 
We conducted a retrospective cohort study comparing young people who started ART in 
the period July 1st, 2014 to December 31st, 2016 to a historical cohort that was treated in January 
1st, 2012 to 30th June 2014 before the policy change. We used administrative data from the 
District Health Information System (DHIS2) and the national referral hospital’s EMR. This data, 
routinely collected from patients who receive HIV treatment at the health facilities during clinic 
visits, is used to plan and monitor a patient’s treatment from the date of HIV diagnosis to the 
date he/she leaves the clinic either through transfer-out to another clinic, lost to follow-up (LTFU) 
or death.  
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Study Cohort 
All individuals that were 15-24 years old at the time of ART initiation were included in the 
study. We also included young people who had been diagnosed prior to or during the study 
period but had not started ART. They also had at least 2 visits of follow-up data, started ART at 
the selected ART clinics and were on lifelong ART. Patients who were LTFU or transferred-out 
were considered for the period when they were in care.  We excluded patients who were lost- 
to- follow-up before the start of the study period, started ART for Pre-exposure prophylaxis (PrEP) 
because it is short term, had no records, and had started ART elsewhere (transfer-in) for lack of 
information from the referral health facility. We also excluded patients who had no follow up 
visit after ART initiation. 
 
Dependent Variable 
The dependent variable “ART adherence” was defined as the percent adherence for each patient 
during the first 12 months of starting ART.  This was coded as a binary variable, “1” if the patient 
had an ART adherence code corresponding to ≥95% adherence and “0”, otherwise. An adherence 
rate of ≥95% is the threshold necessary for sustained clinical effectiveness of ART9,29,30.  A young 
person was considered to be adherent if he/she had a code of “1” for all the months at 3, 6 and 
12 months of follow-up. An individual was considered to be less adherent if he/she had a code of 
“0” for any of the months at 3, 6 and 12 months of follow-up. 
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Independent Variables 
The independent variable of interest was a binary time variable representing the before 
and after introduction of the guidelines (pre-policy=0, post-policy=1). The pre-policy group 
included young people who started ART before July 2014 (January 2012 – June 2014) and the 
post-policy group included young people who started ART after July 2014 (July 2014-December 
2016).  The socio-demographic variables were ART clinic, gender and age at ART start. The clinical 
characteristics were weight, OI at ART start (Yes, No) and WHO clinical disease stage (I, II, III &IV) 
at ART start. The treatment characteristics included duration in pre-ART care (less than 1 month, 
1 month or more), ARV drug regimen (TDF, Non-TDF), the number of ARV pills per day (1 pill, 2 
pills or more) given at ART start, cotrimoxazole prophylaxis at ART start (Yes, No). 
 
Analysis  
All statistical analyses were performed using STATA 15. The unit of analysis was the 
patient. We described and compared patient characteristics using T-tests and Pearson’s chi-
squared tests, respectively (Table 1). All p-values were two-tailed and considered statistically 
significant at α=0.05. We examined the data to ensure that there were no sparse cells. The 
duration in pre-ART care was right-skewed and we categorized it to reduce on the wide variability 
between patients and have more interpretable cutoff points.   To assess associations of each 
independent variable with the dependent variable, ART adherence, univariable analyses were 
first performed.  We conducted multivariable logistic regression analyses to determine the effect 
of the change in policy on ART adherence, controlling for variables at the start of ART that 
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included age, sex, weight, WHO clinical disease stage, duration in pre-ART care, ARV regimen and 
ARV pills per day given. All variables that were statistically significant at p-value <0.25 or had prior 
clinical significance for ART adherence from the univariable analysis, were included in a 
multivariable regression model. We checked the correlation between the variables to ensure that 
none was highly correlated. Possible interactions were also checked and none of them was 
significant. We report the unadjusted and adjusted odds ratios, and 95% confidence intervals in 
Table 3. 
 
IRB approval 
The study was approved by the Makerere University School of Public Health, Uganda 
National Council of Science and Technology, Baylor College of Medicine’s Institutional Review 
Board, and Committee for the Protection of Human Subjects at the University of Texas Health 
Sciences Center at Houston.  
 
Results 
Out of a total of 3532 young people who were initiated on ART in the study period across 
the four study sites, 448 did not meet the inclusion-exclusion criteria and were excluded from 
this analysis. Of the remaining 3084 patients, 50.1% started ART before and 49.9% started ART 
after the policy change. In both groups, young people were more likely to be female and of older 
age (20-24 years). They were less likely to have an OI at the start of treatment, but the percentage 
was higher in the pre-policy group (23.54%) compared to the post-policy group (18.60%). 
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Although young people were more likely to be disease stage I or II at ART stage, the post-policy 
group had a bigger percentage of stage I and less stage II patients compared to the pre-policy 
group. The group differences were significant. Concerning treatment characteristics, starting 
treatment in less than a month of testing HIV positive was observed in both groups. However, 
the post-group had more numbers (93.17%) compared to the pre-group (88.23). On further 
analysis, 43.54% in the post-group started ART the same day they tested HIV positive compared 
to 29.12% in the pre-group. Post-policy young people were more likely to be given a TDF-based 
regimen (93%), one pill a day (86%) compared to the pre-policy group (66% & 45%, respectively). 
The pre-policy group was also more likely to be given non-TDF regimen (34.35%) and 2 or more 
pills per day (54.66%) compared to the post-group (7.41% & 14.43%, respectively). 
Regarding our study outcome, we found that although overall more than 80% of young 
people were adherent at 3, 6 and 12 months of follow-up, we observed a gradual decline in 
both groups over time (Figures 3 & 4). There were no significant group differences at any of 
time points. 
In both the unadjusted and adjusted models, the policy did not have an effect on ART 
adherence (Table 3). Age at ART start, WHO disease stage and the number of ARV pills per day 
were only statistically significant in the unadjusted models at all three time points.  Gender did 
not have an effect on ART adherence, as were weight at ART start, and cotrimoxazole prophylaxis 
in all models.  Younger age (15-19 years) was only significant in the unadjusted model and was 
associated with being less adherent.  In the adjusted model, only the ART clinic providing the 
treatment had an effect on ART adherence at 3, 6 and 12 months on ART. In both the unadjusted 
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and adjusted model, young people in clinics 2, 3, and 4 more likely to be adherent compared to 
the young people receiving treatment in ART clinic 1. Also, after controlling for the independent 
variables in the model, young people who had an OI at ART start were more likely to be adherent 
compared to young people who did not have an OI at ART start, at 6 months (AOR 1.60, 95% CI: 
1.16, 2.21) and 12 months (AOR 1.34, 95% CI: 1.01, 1.77) on ART.  This result was statistically 
significant. Young people who had disease stage II, III and IV disease had lesser odds of being 
adherent compared to those with stage I at ART start. The odds reduced as severity of disease 
increased. Young people who were in pre-ART care for more than one month had a very 
significant effect on ART adherence only in the unadjusted models, similar to young people who 
were given one ARV pill per day.   
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Table 2: Descriptive Statistics of Young People who started ART before and after the Policy 
Change 
Characteristic Pre-2014 policy  Post-2014 policy 
Total  1546 1538 
Dependent Variable   
ART Adherence    
3 months   
Adherent 89.11% 88.46% 
Less Adherent 10.89%  11.54%  
   
6 months   
Adherent 85.98%  84.80%  
Less Adherent 14.02%  15.20% 
   
12 months   
Adherent 82.21%  79.43%  
Less Adherent 17.79%  20.57% 
   
Independent Variables   
Policy change group   
Pre-Policy 50.13%   
Post- Policy  49.87%  
   
Year of ART initiation    
2012 (reference) 28.78%   
2013 47.54%   
2014 23.67%  27.57%  
2015  36.74%  
2016  35.70%  
Socio-Demographic Characteristics   
Age at ART start in years (%)   
15-19 28.91% 28.67% 
20-24  71.09% 71.33% 
   
Gender (%)   
Male  14.81% 13.72% 
Female 85.19%  86.23%  
   
55 
 
Characteristic Pre-2014 policy  Post-2014 policy 
Total  1546 1538 
Weight at ART start in kgs (mean, SD) 55.26(10.15)  55.45(9.30)  
   
Health Facility (%)   
ART clinic 1   15.46% * 16.64% * 
ART clinic 2 39.72% * 31.99% * 
ART clinic 3 10.93% * 10.14% * 
ART clinic 4  33.89% * 41.22% * 
   
Clinical Characteristics   
Had an OI at ART Start (%)   
Yes 23.54% * 18.60% * 
No  76.46% * 81.40% * 
   
WHO disease stage at ART start (%)   
Stage I  57.32% * 75.36%* 
Stage II 32.25% * 17.30% * 
Stage III & IV 10.43% * 7.34% * 
   
Treatment Characteristics   
Duration in Pre –ART care in months (%)   
<1 month 88.23% * 93.17% * 
1 month + 11.77% * 6.38% * 
   
ARV regimen given at ART start (%)   
TDF 65.65% * 92.59% * 
Non-TDF 34.35% * 7.41% * 
   
ARV pills per day at ART start (%)   
1 pill 45.34% * 85.57% * 
2 pills or more 54.66% * 14.43% * 
   
Cotrimoxazole Prophylaxis at ART start (%)   
Yes 97.67% * 99.09% * 
No (reference) 2.33% * 0.91% * 
*Significant at P<0.05   
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Figure 3: Trends of Adherent Young by Year of ART Initiation, before and after Policy Change 
 
Figure 4: Trends of Less Adherent Young by Year of ART Initiation, before and after Policy 
Change 
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Table 3: The Effect of the Independent Variables on ART Adherence among Young People before and after the Policy Change 
 3 months after ART start 6 months after ART start 12 months after ART start 
 Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Policy Change Group 
Pre/Post Group       
Pre-2014 policy Reference Reference Reference Reference Reference Reference 
Post-2014 policy 0.95 (0.74, 1.21) 0.99 (0.73, 1.35) 0.92 (0.75, 1.14) 0.95 (0.73, 1.25) 0.84 (0.70, 1.02) 0.84 (0.66, 1.07) 
Patient socio-demographic characteristics 
Age at Art start (years)       
15-19  0.53 (0.41, 0.68) ** 1.13 (0.83, 1.55) 0.57 (0.46, 0.71) ** 1.13 (0.85, 1.50) 0.61 (0.50, 0.74) ** 1.12 (0.87, 1.45) 
20-24 Reference Reference Reference Reference Reference Reference 
Gender       
Male 0.94 (0.67, 1.31) 1.11 (0.75, 1.64) 0.93 (0.69, 1.24) 1.09 (0.77, 1.55) 0.99 (0.76, 1.29) 1.18 (0.86, 1.63) 
Female Reference Reference Reference Reference Reference Reference 
ART Clinic       
ART Clinic 1 Reference Reference Reference Reference Reference Reference 
ART Clinic 2 16.66 11.42, 24.31) ** 21.98 (13.58, 35.59) ** 16.48 (11.82, 22.99) ** 22.67 (14.65. 35.07) ** 16.81 (12.47, 22.67) ** 25.23 (16.73, 38.03) ** 
ART Clinic 3 4.84 (3.02, 7.78) ** 6.27 (3.50, 11.22) ** 4.74 (3.19, 7.03) ** 6.42 (3.89, 10.62) ** 4.13 (2.94, 5.80) ** 5.53 (3.53, 8.67) ** 
ART Clinic 4 11.37 (8.14, 15.87) ** 14.25 (9.24, 21.97) ** 8.49 (6.44, 11.20) ** 11.47 (7.80, 16.85) ** 7.86 (6.11, 10.10) ** 11.14 (7.72, 16.07) ** 
Patient Clinical Characteristics 
Weight at ART start 1.01 (1.00, 1.03) 1.00 (0.99, 1.02) 1.01 (1.00, 1.02) 1.00 (0.99, 1.01) 1.01 (1.00, 1.02) ** 1.00 (0.99, 1.01) 
Had an OI at ART Start       
Yes 1.15 (0.84, 1.56) 1.31 (0.92, 1.86) 1.25 (0.95, 1.64) 1.60 (1.16, 2.21) ** 1.10 (0.87. 1.39) 1.34 (1.01, 1.77) * 
No Reference Reference Reference Reference Reference Reference 
WHO Disease Stage at ART start      
Stage I Reference Reference Reference Reference Reference Reference 
Stage II 0.67 (0.51, 0.89) ** 1.24 (0.88, 1.74) 0.71 (0.56, 0.91) ** 1.21 (0.89, 1.64) 0.72 (0.58, 0.90) ** 1.18 (0.89, 1.55) 
Stage III & IV 0.60 (0.40, 0.90) ** 0.90 (0.54, 1.50) 0.58 (0.41, 0.83) ** 0.79 (0.50, 1.25) 0.60 (0.43, 0.83) ** 0.76 (0.50, 1.16) 
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 3 months after ART start 6 months after ART start 12 months after ART start 
 Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Patient’s Treatment Characteristics 
Duration in Pre-ART care      
< 1 month Reference Reference Reference Reference Reference Reference 
One Month or 
more 
0.16 (0.12, 0.21) ** 1.28 (0.85, 1.94) 0.17 (0.13, 0.22) ** 1.31 (0.88, 1.95) 0.18 (0.14, 0.23) ** 1.42 (0.95, 2.12) 
ARV Regimen at ART start      
TDF 0.83 (0.61, 1.13) 1.15 (0.75, 1.77) 0.87 (0.66, 1.13) 1.20 (0.82, 1.77) 0.87 (0.69, 1.10) 1.15 (0.81, 1.62) 
Non-TDF Reference Reference Reference Reference Reference Reference 
ARV Pills per day       
1 pill 0.77 (0.59, 1.00) * 1.03 (0.70, 1.52) 0.78 (0.62, 0.98) * 1.04 (0.73, 1.46) 0.81 (0.66, 0.99) * 1.20 (0.88, 1.63) 
2 pills or more Reference Reference Reference Reference Reference Reference 
Cotrimoxazole prophylaxis at ART start      
Yes 0.76 (0.23, 2.51) 0.57 (0.07, 4.39) 1.06 (0.44, 2.55) 0.94 (0.27, 3.28) 0.81 (0.36, 1.84) 0.76 (0.25, 2.29) 
No Reference Reference Reference Reference Reference Reference 
*Significant at p-value 0.05 
**Significant at p-value 0.01 
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Discussion  
This study gives an insight into the effect of 2014 ART policy change on ART adherence 
among young people, ages 15-24 years in Uganda. Our study found that ART adherence declined 
as the duration on ART increased. Whereas the percentage of adherent young people decreased 
at 3, 6 and 12 months, it increased for the less adherent young people (Figure 3 & 4). The increase 
is observed more in young people who initiated ART in 2015 and 2016. This could be attributed 
to inadequate preparation of young people for ART especially in the post-policy period where the 
duration between HIV diagnosis and ART initiation was reduced. Our study had more than 40% 
young people that started ART the same day they were diagnosed with HIV and could have 
contributed to this result. Given that the success of HIV care is dependent on the patient’s right 
and willingness to accept or defer treatment39, we can therefore argue that these young people 
may not have grasped the implications of the lifelong ART whose success depends on maintaining 
high levels of adherence to keep the viral load low. Our findings are similar to other studies that 
have reported poor ART adherence among relatively healthier patients starting ART early40,41,42. 
We also know that one’s attitude and perceptions have an effect on health behavior43. Some may 
not realize the importance of daily medication since they do not feel sick and some may still have 
the belief that starting ART is a death sentence as has been reported elsewhere25,26.  Therefore, 
health professionals need to emphasize the importance of adhering to the daily medication and 
the benefits of ART when initiating treatment in young people.   
Contrary to expectation, in our study the policy change did not have an effect on ART 
adherence. However, we found the ART clinic providing treatment was the main driver of ART 
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adherence at 3, 6 and 12 months.  In the Donabedian model, structure is defined as “the 
conditions under which care is provided, including material resources, human resources, and 
organizational characteristics”42. In order to provide quality HIV treatment, adequate physical 
and human resources have to be available. Given that there was variability in how adherence is 
measured, staffing levels, infrastructure and location of the ART clinics involved in the study, 
though not the focus of this study, this may have influenced our results.  In our study ART 
adherence differs by health facility and therefore more research is needed to identify those 
factors contributing to this result. 
We also found that having an OI at ART start had an effect on ART adherence at 6 and 12 
months, after adjusting for other variables in the model.  Young people who had an OI at ART 
start had 60% and 34% higher odds of being adherent at 6 and 12 months on ART compared to 
young people who did not have an OI at ART start. Although having an OI at ART start increases 
the chances of complications that are common during the first months on ART44, the desire to be 
healthier and stronger may be the motivation to adhere to treatment.  
This study had a number of strengths. To our knowledge this is the first study to evaluate 
the effect of changes in ART policy on ART adherence among young people in Uganda. We had a 
large study cohort of young people from 4 large volume HIV clinics that are representative of the 
4 geographical regions in Uganda. The different regions capture the regional variation and 
therefore increase generalizability of the study results. Our results must however be interpreted 
in light of several limitations. We did not capture socio-demographic data on education and 
marital status which may or may not have yielded different results given younger age was 
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associated with being in school and the older young people were more likely to be married. The 
variability in adherence measurement may have limited our ability to provide more generalizable 
results. Despite the limitations the study results are still generalizable to high volume health 
facilities in Uganda.   
 
Conclusion 
This study found that ART adherence among young people was mainly driven by 
differences between health facilities providing ART in Uganda and whether an individual had an 
OI at ART start. Although our study did not find an effect between policy change and ART 
adherence, young people starting ART much earlier will lead to a higher treatment burden, and 
this might negatively impact ART adherence over time. Therefore, whereas initiating treatment 
before onset of advanced disease is beneficial, the implications on long term adherence cannot 
be overlooked. We believe that there are factors influencing adherence that are not captured by 
our study, that need further investigation.  
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JOURNAL ARTICLE 2 
The Effect of Changes in Antiretroviral Therapy Policy on Opportunistic Infections among Young 
People living with HIV in Uganda. 
Abstract  
Objectives: For optimal benefits of life-saving antiretroviral therapy (ART) for people living with 
the Human Immunodeficiency Virus (HIV), the ART eligibility criterion has continually been 
revised to start treatment before advanced disease stages. We evaluated the effect of the 
changes in the ART policy on opportunistic infections among young people, aged 15-24 years. 
Methods: This was a retrospective analysis of young people living with HIV, 15-24years old, who 
started ART from January 2012 – December 2016. This study used administrative data from the 
District Health Information System (DHIS2) and the national referral hospital. We compared 
young people who started ART before and after the policy change and assessed the effect of that 
change on opportunistic infections, using multivariable logistic regression. 
Results: On average, young people who started ART after the policy change had lesser odds of 
having an OI compared to those who started ART before the policy at 3, 6 and 12 months on ART. 
Age, the health facility, weight, and WHO disease stage were also associated with having OIs, as 
well as duration in pre-ART care, ARV regimen and number of pills per day. Cotrimoxazole 
prophylaxis did not have an effect on OIs. 
Conclusion: Post-Policy young people were less likely to have OIs compared those who started 
ART before the policy change. OIs declined over time. The positive trend is attributable to early 
ART initiation, with less advanced disease, in addition to the use of more potent ARVs.  However, 
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there are still OIs that persist among PLWH and further research will help identify them and 
design interventions to mitigate the problem.  
 
Introduction  
Despite the introduction of life-saving antiretroviral therapy (ART) for treatment and 
prevention of the Human Immunodeficiency Virus (HIV), it continues to be a public health threat 
in sub-Saharan Africa.  In Uganda, the 4% prevalence rate among young people, the increase in 
new infections and number of children who were perinatally infected with HIV becoming 
adolescents and adults, is a concern for health professionals and policy makers3. AIDS-related 
mortality is still high and opportunistic infections (OI) are still a major cause of death among those 
whose treatment is not keeping their viral load low enough to fight off infections. Between 2005 
and 2012, the number of deaths among this age group increased by 50% whereas overall it had 
decreased by 30%48.  It is within this context that efforts were made to maximize the benefits of 
ART by revising policies to initiate treatment before the onset of advanced disease. With initiation 
at a higher CD4 count threshold, ART can prevent the majority of these infections and deaths 3-8. 
The WHO estimates that ART has saved 11.4 million lives worldwide over the last decade34. 
Whereas high income countries started initiating ART for all people living with HIV/AIDS 
immediately after diagnosis, as early as the year 2000, it was not the case for low- and middle-
income countries (LMICs).  LMICs adopted a more gradual approach to the test and treat strategy 
considering cost and demands it would place on already weak healthcare systems. In July 2014, 
Uganda adopted the 2013 ART guidelines.  All young people were initiated on ART at CD4 cell 
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count ≤500 cells/mm3 regardless of clinical disease stage, using once-a day fixed-dose 
combination regimens. Despite the increased ART coverage, the threat posed by a higher 
treatment burden in addition to poor adherence cannot be overlooked. Opportunistic infections 
still exist among young people and these negatively affect their quality of life and increase the 
risk of death15,31,34,49,50  
Although several studies have assessed the OIs, they focused more on infants, children 
and adults and less on young people.  In addition, OIs vary by region and age. Providing country-
specific data will help define local priorities, reduce barriers to, and improve treatment 
outcomes. We therefore evaluated the effect of the changes in the 2014 ART policy on 
opportunistic infections among young people, aged 15-24 years in Uganda.   
 
Methods 
Study Design and Data Source 
For this retrospective cohort study, we used administrative data from the District Health 
Information System (DHIS2) and the national referral hospital’s EMR.  We compared young 
people who started ART in the period July 1st, 2014 to December 31st, 2016 to a cohort that was 
treated in January 1st, 2012 to 30th June 2014 before the policy change. This data, routinely 
collected from patients who receive HIV treatment at the ART clinics during routine visits, is used 
to monitor a patient’s treatment from the date of HIV diagnosis to the date he/she leaves the 
clinic either through transfer-out to another clinic, lost to follow-up (LTFU) or death.  
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Study Cohort 
We included all individuals that were 15-24 years old at the time of ART initiation.  Young 
people diagnosed prior to or during the study period but had not started ART, were also included 
in the study. Those who had at least 2 visits of follow-up data, started ART at the selected ART 
clinics and were on lifelong ART were included. Young people who were LTFU or transfer-out 
during the study period were included because they contributed time until the event happened. 
However, we excluded patients who were lost- to- follow-up before the start of the study period 
and those on Pre-exposure prophylaxis (PrEP) because it is short term. Individuals with no 
records, and had started ART elsewhere were excluded because of lack of information from the 
referral clinic. Patients who had no follow-up visit after ART initiation were also excluded. 
 
Dependent Variable 
We defined the dependent variable “opportunistic infection” as a disease event diagnosed during 
a clinic visit and recorded in the patient’s medical record as an OI. This was coded as a binary 
variable, “1” if the patient had an OI during the months after starting ART and “0” otherwise. A 
young person was considered to have an OI if he/she had a code of “1” for any of the months at 
3, 6 and 12 months of follow-up. An individual who had an OI at 3 months, was also considered 
to have an OI at 6 and 12 months. 
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Independent Variables 
One of the independent variables of interest was a binary time variable (pre-2014 policy =0, post-
2014 policy=1). The other independent variable of interest was the year of ART initiation (2012, 
2013, 2014, 2015, 2016). The pre-policy group included young people who started ART from 
January 2012 – June 2014 and the post-policy group included those who started ART from July 
2014-December 2016. The socio-demographic variables were ART clinic, gender and age at ART 
start. The clinical characteristics were weight, OI at ART start (Yes, No) and WHO clinical disease 
stage (I, II, III&IV) at ART start. The treatment characteristics included duration in pre-ART care 
(less than 1 month, 1 month or more), ARV drug regimen (TDF, Non-TDF), the number of ARV 
pills per day (1 pill, 2 pills or more) given at ART start, cotrimoxazole prophylaxis at ART start (Yes, 
No) and ART adherence (adherent, less adherent) during the follow-up time after starting ART. 
 
Analysis 
All statistical analyses were performed using STATA 15. We described and compared patient 
characteristics using T-tests and Pearson’s chi-squared tests, respectively (Table 4). All p-values 
were two-tailed and considered statistically significant at α=0.05. To assess associations of each 
independent variable with the dependent variable, opportunistic infection, univariable analyses 
were first performed.  We conducted multivariable logistic regression analyses to determine the 
effect of the change in policy on opportunistic infections, controlling for all the independent 
variables mentioned above. All variables that were statistically significant at p-value <0.25 or had 
prior clinical significance for OIs from the univariable analysis, were included in the multivariable 
73 
 
regression models. We checked the correlation between the variables to ensure that none was 
highly correlated. Possible interactions were also checked and none of them was significant. We 
run three separate regression models at 3 months, 6 months and 12 months to see if the change 
in policy was successful in keeping the infections low. We report the unadjusted and adjusted 
odds ratios, and 95% confidence intervals in Table 2. 
 
 IRB approval 
The study was approved by the Makerere University School of Public Health, Uganda 
National Council of Science and Technology, Baylor College of Medicine’s Institutional Review 
Board, and Committee for the Protection of Human Subjects at the University of Texas Health 
Sciences Center at Houston.  
 
Results 
This analysis included data from 3084 young people who met the inclusion-exclusion 
criteria out of 3532. 50.13% of these started ART before and 49.87% started ART after the policy 
change. Although there were no significant group differences in age at ART start and gender, 
young people were more likely to be older (20-24 years) and female. The number of young people 
initiating ART was different between clinics, but within the clinics there was not much difference, 
pre- and post- policy. More than 76% of young people did not have an OI at ART initiation in both 
groups.  But among those who had an OI, the pre-policy group was bigger (23.54%) compared to 
18.60% in the post-policy group. 57% pre-policy and 75% post-policy young people started ART 
74 
 
with stage I disease. The pre-policy group had more young people (32%) starting ART with stage 
II disease compared to post-policy group (17%).  In both groups, ART initiation was in less than a 
month of testing HIV positive. However, the post-policy group had a bigger percentage (93%) 
compared to the pre-policy group (88%). A sub-analysis showed that among those who started 
ART in less than a month, nearly 50% in the post-group and 30% in the pre-group started ART the 
same day they tested positive for HIV. More young people in the pre-policy group (11.77%) 
stayed in pre-ART care more than a month. Post-policy young people were more likely to be given 
a TDF-based regimen (93%) and one pill a day (86%). Almost all the young people in both groups 
were given cotrimoxazole prophylaxis at ART start.   
With regards to our study outcome, there were significant group differences between 
young people who had an OI at 3, 6 and 12 months after starting ART. The percentage of young 
people with OIs declined especially after the policy changed in 2014 (Figure 5).  
Starting ART pre-policy or post-post was significantly associated with having an OI at all 
three time points, in the unadjusted models at 3 and 6 months on ART and in both the unadjusted 
and adjusted models at 12 months on ART. Post-policy young people had less odds of having an 
OI after starting ART and these odds continued to decline over time (Table 5 and 6). Younger age 
(15-19 years) was associated with lesser odds of having an OI in all the three unadjusted models. 
But the odds did not change over time.  Male young people had higher odds of having an OI in 
the unadjusted models. There were significant differences between the ART clinics providing 
treatment. Young people who received treatment at ART clinic 3 had lesser odds of OIs and those 
at clinics 2 and 4 had higher odds of OIs compared to those in clinic 1. Having an OI at ART start 
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increased the odds of having one after ART initiation in all 6 models. WHO disease stage was 
significant in all the models and at all the time points. Young people with disease stage II, III and 
IV at ART start had higher odds of having an OI compared to young people with stage I, and the 
odds declined over time. Young people who started ART a month or more after being diagnosed 
with HIV, had higher odds of having an OI compared to those with a shorter duration in pre-ART. 
Whereas ARV regimen and the number of pills per day given at ART start had an effect on OIs, 
cotrimoxazole prophylaxis did not.  
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Table 4: Descriptive Statistics of Young People who started ART before and after the Policy 
Change 
Characteristic Pre-2014 policy  Post-2014 policy 
Total  1546 1538 
Dependent Variable   
Had on OI    
3 months   
Yes 48.05%  35.84%  
No 51.95%  64.16%  
6 months   
Yes 54.02%  40.54%  
No 45.98% 59.46%  
12 months   
Yes 60.77%  44.97%  
No 39.23%  55.03%  
Independent Variables   
Policy change group   
Pre-Policy 50.13%   
Post- Policy  49.87%  
Year of ART initiation    
2012 (reference) 28.78%   
2013 47.54%   
2014 23.67%  27.57%  
2015  36.74%  
2016  35.70%  
Socio-Demographic Characteristics   
Age at ART start in years (%)   
15-19 28.91% 28.67% 
20-24  71.09% 71.33% 
Gender (%)   
Male  14.81% 13.72% 
Female 85.19%  86.23%  
   
Weight at ART start in kgs (mean, SD) 55.26(10.15)  55.45(9.30)  
   
Health Facility (%)   
ART clinic 1   15.46% * 16.64% * 
ART clinic 2 39.72% * 31.99% * 
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Characteristic Pre-2014 policy  Post-2014 policy 
Total  1546 1538 
ART clinic 3 10.93% * 10.14% * 
ART clinic 4  33.89% * 41.22% * 
Clinical Characteristics   
Had an OI at ART Start (%)   
Yes 23.54% * 18.60% * 
No  76.46% * 81.40% * 
WHO disease stage at ART start (%)   
Stage I  57.32% * 75.36%* 
Stage II 32.25% * 17.30% * 
Stage III & IV 10.43% * 7.34% * 
Treatment Characteristics   
Duration in Pre –ART care in months (%)   
<1 month 88.23% * 93.17% * 
1 month + 11.77% * 6.38% * 
ARV regimen given at ART start (%)   
TDF 65.65% * 92.59% * 
Non-TDF 34.35% * 7.41% * 
ARV pills per day at ART start (%)   
1 pill 45.34% * 85.57% * 
2 pills or more 54.66% * 14.43% * 
Cotrimoxazole Prophylaxis at ART start (%)   
Yes 97.67% * 99.09% * 
No (reference) 2.33% * 0.91% * 
ART Adherence at 3 months   
Adherent 89.11% 88.46% 
Less Adherent 10.89%  11.54%  
ART Adherence at 6 months   
Adherent 85.98%  84.80%  
Less Adherent 14.02%  15.20% 
ART Adherence at 12 months   
Adherent 82.21%  79.43%  
Less Adherent 17.79%  20.57% 
*Significant at P<0.05   
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Figure 5: Trends in Percentage of Young People with Opportunistic Infections at 3, 6 and 12 
Months after ART Initiation 
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Table 5: The Effect of the Independent Variables on Opportunistic Infections among HIV Positive Young People on ART, before 
and after the 2014 ART Policy Change 
 3 months after ART start 6 months after ART start 12 months after ART start 
 Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Policy Change Group 
Pre/Post Group       
Pre-2014 policy Reference Reference Reference Reference Reference Reference 
Post-2014 policy 0.60(0.52, 0.70) ** 0.85 (0.70, 1.05) 0.58 (0.50. 0.67) ** 0.82 (0.67, 1.00) 0.53 (0.46, 0.61) ** 0.70 (0.58, 0.85) ** 
Patient socio-demographic characteristics 
Age at Art start (years)       
15-19  0.88(0.75, 1.04) 0.77 (0.63, 0.95) * 0.88 (0.76, 1.03) 0.77 (0.63, 0.95) * 0.87 (0.74, 1.02) 0.77 (0.63, 0.93) ** 
20-24 Reference Reference Reference Reference Reference Reference 
Gender       
Male 1.64 (1.34, 2.01) ** 1.12 (0.86, 1.47) 1.66 (0.35, 2.04) ** 1.15 (0.89, 1.50) 1.55 (1.26, 1.92) ** 1.10 (0.85, 1.42) 
Female Reference Reference Reference Reference Reference Reference 
ART Clinic       
ART Clinic 1 Reference Reference Reference Reference Reference Reference 
ART Clinic 2 0.76 0.62, 0.95) ** 1.18 (0.80, 1.75) 0.73 (0.59, 0.91) ** 1.25 (0.86, 1.84) 0.73 (0.59, 0.91) ** 1.08 (0.75, 1.56) 
ART Clinic 3 0.38 (0.28, 0.52) ** 0.43 (0.26, 0.70) ** 0.40 (0.30, 0.54) ** 0.51 (0.32, 0.81) ** 0.43 (0.32, 0.58) ** 0.52 (0.34, 0.82) ** 
ART Clinic 4 0.92 (0.75, 1.14)  1.88 (1.28, 2.78) ** 0.94 (0.76, 1.16) 2.09 (1.43, 3.06) ** 0.98 (0.79, 1.21) 1.81 (1.26, 2.61) ** 
       
Patient Clinical Characteristics 
Weight at ART start 0.97 (0.97, 0.98) ** 0.99 (0.98, 1.00) * 0.97 (0.97. 0.98) ** 0.99 (0.98, 1.00) * 0.98 (0.97, 0.99) ** 0.99 (0.98, 1.00) * 
Had an OI at ART start       
Yes 20.92 (16.00, 27.34) ** 14.70 (11.09, 19.50) ** 18.13 (13.67,24.05) ** 12.96 (9.63, 17.43) ** 15.60 (11.59, 21.00) ** 10.92 (8.01, 14.88) ** 
No  Reference     
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 3 months after ART start 6 months after ART start 12 months after ART start 
 Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
WHO Disease Stage at ART start      
Stage I Reference Reference Reference Reference Reference Reference 
Stage II 2.63 (2.21, 3.14) ** 2.08 (1.65, 2.62) ** 2.42 (2.03, 2.88) ** 1.80 (1.44, 2.25) ** 2.35 (1.97, 2.81) ** 1.71 (1.37, 2.14) ** 
Stage III & IV 7.68 (5.59, 10.55) ** 4.27 (2.88, 6.34) ** 7.36 (5.25, 10.33) ** 3.97 (2.65, 5.96) ** 6.25 (4.40, 8.88) ** 3.32 (2.20, 5.02) ** 
Patient’s Treatment Characteristics 
Duration in Pre-ART care      
< 1 month Reference Reference Reference Reference Reference Reference 
One Month or 
more 
1.60 (1.25, 2.05) ** 1.75 (1.12, 2.74) * 1.76 (1.37, 2.26) ** 2.21 (1.42. 3.44) ** 1.68 (1.30. 2.16) ** 1.78 (1.16, 2.74) ** 
ARV Regimen at ART start      
TDF 0.45(0.38, 0.54) ** 0.73 (0.56, 0.97) * 0.46 (0.38, 0.55) ** 0.73 (0.55. 0.95) * 0.43 (0.36, 0.52) ** 0.67 (0.51, 0.88) ** 
Non-TDF Reference Reference Reference Reference Reference Reference 
ARV Pills per day       
1 pill 0.52 (0.44, 0.60) ** 0.63 (0.49, 0.81) ** 0.52 (0.45. 0.61) ** 0.64 (0.50. 0.81) ** 0.52 (0.45. 0.61) ** 0.70 (0.55, 0.90) ** 
2 pills or more Reference Reference Reference Reference Reference Reference 
Cotrimoxazole prophylaxis at ART start      
Yes 0.88 (0.50, 1.56) 0.79 (0.33, 1.89) 0.66 (0.38, 1.17) 0.53 (0.23, 1.22) 0.70 (0.39, 1.25) 0.65 (0.28, 1.50) 
No Reference Reference Reference Reference Reference Reference 
*Significant at p-value 0.05 
**Significant at p-value 0.01 
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Table 6: The Effect of Year of ART Initiation on Opportunistic Infections among HIV Positive Young People on ART 
 3 months after ART start 6 months after ART start 12 months after ART start 
 Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Year of ART Initiation       
2012 Reference Reference Reference Reference Reference Reference 
2013 0.32 (0.25, 0.41) ** 0.41 (0.30, 0.57) ** 0.32 (0.25, 0.41) ** 0.45 (0.33, 0.61) ** 0.37 90.29, 0.49) ** 0.54 (0.39, 0.74) ** 
2014 0.44 (0.35, 0.56) ** 0.62 (0.45, 0.85) ** 0.43 (0.34, 0.56) ** 0.67 (0.49, 0.92) * 0.43 (0.33, 0.56) ** 0.65, (0.47, 0.90) ** 
2015 0.29 (0.22, 0.37) ** 0.48 (0.34, 0.68) ** 0.28 (0.22, 0.37) ** 0.50, (0.35, 0.71) ** 0.27 (0.21, 0.35) **  0.44 (0.31, 0.63) ** 
2016 0.19 (0.15, 0.25) ** 0.28 (0.19, 0.41) ** 0.17 (0.13, 0.22) ** 0.25 (0.17, 0.36) ** 0.16 (0.12, 0.22) ** 0.24 (0.17, 0.35) ** 
Patient socio-demographic characteristics 
Age at Art start (years)       
15-19  0.88(0.75, 1.04) 0.77 (0.63, 0.96) * 0.88 (0.76, 1.03) 0.77 90.63, 0.95) * 0.87 (0.74, 1.02) 0.77 (0.63, 0.94) ** 
20-24 Reference Reference Reference Reference Reference Reference 
Gender       
Male 1.64 (1.34, 2.01) ** 1.10 (0.84, 1.44) 1.66 (1.35, 2.04) ** 1.14 (0.88, 1.49) 1.55 (1.26, 1.92) ** 1.09 (0.84, 1.42) 
Female Reference Reference Reference Reference Reference Reference 
ART Clinic       
ART Clinic 1 Reference Reference Reference Reference Reference Reference 
ART Clinic 2 0.76 0.62, 0.95) ** 1.07 (0.72, 1.59) 0.73 (0.59, 0.91) ** 1.10 (0.75, 1.63) 0.73 (0.59, 0.91) ** 0.94 (0.64, 1.36) 
ART Clinic 3 0.38 (0.28, 0.52) ** 0.38 (0.23, 0.63) ** 0.40 (0.30, 0.54) ** 0.45 (0.28, 0.72) ** 0.43 (0.32, 0.58) ** 0.45 (0.29, 0.71) ** 
ART Clinic 4 0.92 (0.75, 1.14)  1.68 91.13, 2.50) ** 0.94 (0.76, 1.16) 1.84 (1.25, 2.72) ** 0.98 (0.79, 1.21) 1.58 (1.09, 2.30) * 
       
Patient Clinical Characteristics 
Weight at ART start 0.97 (0.97, 0.98) ** 0.99 (0.98, 1.00) ** 0.97 (0.97. 0.98) ** 0.99 (0.98, 1.00) * 0.98 (0.97, 0.99) ** 0.99 (0.98, 1.00) 
Had an OI at ART start       
Yes 20.92 (16.00, 27.34) ** 14.81 (11.14, 19.70) ** 18.13 (13.67,24.05) ** 13.12 (9.72, 17.73) ** 15.60 (11.59, 21.00) ** 10.94 (8.00, 14.96) ** 
No Reference Reference Reference Reference Reference Reference 
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 3 months after ART start 6 months after ART start 12 months after ART start 
 Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
Unadjusted Model 
OR (95% CI) 
Adjusted Model 
OR (95% CI) 
WHO Disease Stage at ART start      
Stage I Reference Reference Reference Reference Reference Reference 
Stage II 2.63 (2.21, 3.14) ** 1.99 (1.58, 2.52) ** 2.42 (2.03, 2.88) ** 1.73 (1.37, 2.18) ** 2.35 (1.97, 2.81) ** 1.65 (1.31, 2.07) ** 
Stage III & IV 7.68 (5.59, 10.55) ** 3.84 (2.58, 5.73) ** 7.36 (5.25, 10.33) ** 3.57 (2.36, 5.38) ** 6.25 (4.40, 8.88) ** 3.01 (1.98, 4.57) ** 
Patient’s Treatment Characteristics 
Duration in Pre-ART care      
< 1 month Reference Reference Reference Reference Reference Reference 
One Month or 
more 
1.60 (1.25, 2.05) ** 1.43 (0.91. 2.25) 1.76 (1.37, 2.26) ** 1.79 (1.14, 2.80)* 1.68 (1.30. 2.16) ** 1.46 (0.94, 2.26) 
ARV Regimen at ART start      
TDF 0.45(0.38, 0.54) ** 0.77 (0.58, 1.02) 0.46 (0.38, 0.55) ** 0.75 (0.57, 0.99) * 0.43 (0.36, 0.52) ** 0.69 (0.52, 0.91) ** 
Non-TDF Reference Reference Reference Reference Reference Reference 
ARV Pills per day       
1 pill 0.52 (0.44, 0.60) ** 0.75 (0.58, 0.97) * 0.52 (0.45. 0.61) ** 0.76 (0.59, 0.97) * 0.52 (0.45. 0.61) ** 0.83 (0.65, 1.06) 
2 pills or more Reference Reference Reference Reference Reference Reference 
Cotrimoxazole prophylaxis at ART start      
Yes 0.88 (0.50, 1.56) 0.94 (0.38, 2.31) 0.66 (0.38, 1.17) 0.60 (0.25, 1.42) 0.70 (0.39, 1.25) 0.73 (0.31, 1.73) 
No Reference Reference Reference Reference Reference Reference 
*Significant at p-value 0.05 
**Significant at p-value 0.01 
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Discussion 
In this study, our findings show that young people who started ART after the 2014 ART 
policy change were less likely to have OIs compared to those who started ART before the 
policy change, at all three time points (Table 5 & 6).  The percentage of young people with 
OIs declined over time by year of ART initiation, as more young people were started on ART 
(Figure 5). Although the percentage declined between 2012 and 2013, there was an increase 
between 2013 and 2014. However, after 2014, a gradual decline is observed. This positive 
trend could be attributed to early ART initiation, with less advanced disease, which was 
consistent with the policy change, in addition to the use of more potent ARVs.  In our study, 
young people were started on ART as soon as they are diagnosed with HIV to reduce the risk 
of infections and this could be the reason for the decline over time in OIs and the lesser odds 
of having one in the post-policy group. It is evident in the literature that the risk of getting an 
OI after starting ART are very low unless the patient is not adherent to medication51. Our 
results are not different from other studies done in Uganda and elsewhere in sub-Saharan 
Africa31,52.  A systematic review of the literature found that the risk for all OIs in LMICs 
reduced to <2% during the first year on ART31. But they also noted that OIs still persist in 
PLWH even with ART, similar to what was reported elsewhere20,50,53.  The fact that OIs still 
persist among PLWH could be the reason for the higher and increasing odds of having an OI 
in the pre-policy group. Our findings also show that OIs are still a burden for young people 
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living with HIV and more effort is needed to fully reap the benefits of ART in reducing such 
infections. It should be noted that our study did not disaggregate the OIs and therefore does 
not show the ones that have persisted in the study population.  
Secondly, male young people were more likely to have OIs after ART initiation 
compared to female young people in the adjusted model and at all three time points. This is 
not surprising given that males have been found to be less adherent to ART and therefore at 
increased risk of getting OIs after starting ART. Poor adherence, a major determinant of 
treatment failure increases the risk for OIs27. This finding could be also be attributed to the 
gender differences in the prevalence of some OIs like tuberculosis with the men 
disproportionately affected compared to females as has been reported in the literature51. 
Furthermore, the ART clinic providing the ART treatment had a significant association 
with having an OI after ART initiation. Whereas young people who got their ART at clinic 3 
had lesser odds of OIs, those who got their ART at clinic 4 had higher odds of OIs compared 
to young people at clinic 1. Health facility-based factors and the variation in the regional 
endemicity of certain OIs could be the contributing factor to this result. Though our study did 
not disaggregate OIs, our results are in line with findings by Rubaihayo et. al. (2016) who 
found that TB was endemic to the northern and eastern regions of the country compared to 
other geographical areas because of socio-economic disparities.   
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Our results also show that WHO disease stage at ART start was significantly associated 
with OI occurrence. Young people with stage II, III and IV disease were more likely to have an 
OI compared to those who had stage I disease. Although our study had a large number of 
young people who started ART with stage 1 disease in both groups, the decreasing odds of 
OIs for these advanced disease stages implies that the treatment is succeeding in reducing 
the infections over time.  It is also not surprising that the higher odds of having OIs especially 
during the first months of treatment compared to those with less advanced disease were 
observed.  PLWH who start ART with more advanced disease are more likely to have 
complications that are common during the first months on ART44. These start treatment with 
when they are too ill and have a bigger pill burden consisting of ARVs and other drugs given 
to treat opportunistic infections that are common with that disease stage.  Our findings 
therefore support early initiation of ART before the onset of advanced HIV disease for better 
treatment outcomes on ART since it reduces morbidity and mortality among PLWHA45 .   
ART regimen also had an effect on OIs. Young people who were given TDF-based 
regimen had lesser odds of having an OI after ART initiation. TDF being a more potent ARV 
and the recommended first line regimen7, is therefore effective in keeping the risk of OIs low. 
In line with this, is the finding that young people who were given one ARV pill per day had 
lesser odds of OIs. Therefore, the potency of the ARV drugs coupled with a lesser pill burden 
had a positive impact on reducing opportunistic infections among young people in Uganda. 
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Surprisingly cotrimoxazole prophylaxis (CTX) which is used to reduce on the risk of 
bacterial infections, did not have a significant effect on the dependent variable. This may not 
be surprising since CTX had been recommended for HIV-infected persons with CD4 counts 
<350 cells/mm3 in resource-constrained areas 57. We were limited by the lack of CD4 count 
data at ART start for all the young people in our sample. But for the few who had CD4 count 
data, the mean CD4 count was >500 cells/mm3, and only 30% had <350 cells/mm3. Therefore, 
CTX may not have an effect if a patient has a higher CD4 threshold and this could explain why 
we did not find a significant association. This finding is very useful in light of newer policies 
seeking to phase out cotrimoxazole prophylaxis among adherent PLWH.  
Our study had several strengths. To our knowledge this is the first study to evaluate 
the impact of the changes in the 2014 ART guidelines, on OIs among HIV-infected young 
people living with HIV in Uganda. We had a large study cohort from 4 large volume ART clinics 
that are geographically representative. This regional variation increases the generalizability 
of the study results. This is also one of the few longitudinal studies that analyzed the effect 
of policy changes on OIs.  Our results had some limitations. We lacked socio-demographic 
data on education and marital status. We also lacked data of CD4 count at ART initiation. 
Some unobserved measures may have affected our findings as is common in observational 
studies as well as some other factors that may be contributing to some of the positive trends 
  
87 
 
in declining OIs we observed in this study. However, the study findings are still generalizable 
to other high-volume HIV clinics in Uganda and useful for informing HIV interventions.  
 
 
Conclusion 
 This study demonstrates that early ART initiation reduces morbidity due to HIV over 
time. Young people who initiated ART after the policy change were less likely to have an OI 
after starting treatment. However, there are still OIs that persist among PLWH and further 
research will help identify them and design interventions to mitigate the problem. 
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JOURNAL ARTICLE 3 
The Effect of Changes in Antiretroviral Therapy Policy on survival of Young People living with 
HIV in Uganda. 
Abstract  
Objectives: The introduction of life-saving antiretroviral therapy (ART) has prolonged the 
survival of people living with HIV. Despite this, HIV continues to threaten the survival of young 
people living with the virus. To mitigate this threat, the eligibility criteria was revised to start 
ART early but little has been documented about the effect of these changes. We evaluated 
the effect of the changes in Uganda’s ART policy on survival of young people, aged 15-24 
years. 
Methods: This was a retrospective analysis of young people living with HIV, 15-24years old, 
who started ART between January 2012 and December 2016. This study used administrative 
data from the District Health Information System (DHIS2) and the national referral. We used 
multivariable Cox Proportional Hazards regression to examine the effect of the policy on 
survival. 
Results: There was no significant difference in the survival probabilities and the hazard ratios 
of young people who started ART before and those who started ART after the policy changed. 
However, although not statistically significant, the risk of death among the post-policy group 
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was increased in the adjusted model. WHO disease stage, weight at ART start and ART 
adherence at the time of death had an effect on survival. 
Conclusion: Young people had higher survival probabilities after ART initiation regardless of 
whether they started ART before or after the policy change. However, given that the risk of 
death among the post-policy group was higher and ART adherence had an effect on survival, 
more investigation is needed to identify factors influencing this.   
 
Introduction 
The introduction of life-saving antiretroviral therapy (ART) for treatment and 
prevention of the Human Immunodeficiency Virus (HIV) has saved lives and improved survival 
of people living with the virus (PLWH)23,58. The WHO estimates that ART has saved 11.4 million 
lives worldwide over the last decade34. Despite these achievements, HIV continues to be a 
public health threat in sub-Saharan Africa especially among young people.  In Uganda, the 
HIV prevalence rate among young people is 4%. There has also been an increase in new 
infections. AIDS-related mortality is still high and opportunistic infections (OI) are still a major 
cause of death among those whose treatment is not keeping their viral load low enough to 
fight off infections. Between 2005 and 2012, the number of deaths among this age group 
increased by 50% whereas overall it had decreased by 30%48.  It is within this context that 
efforts were made to maximize the benefits of ART for HIV treatment by revising policies to 
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initiate treatment early in the course of the illness. With initiation at a higher CD4 count 
threshold, ART can prevent the majority of these infections and deaths 3-8. 
Although high income countries adopted the “test and treat strategy” as early as the 
year 2000, low- and middle-income countries (LMICs) used a more gradual approach due to 
cost implications and projected demands on already weak healthcare systems. Uganda 
adopted the 2013 ART guidelines in July 2014 and started initiating ART for all young people 
at CD4 cell count ≤500 cells/mm3, using a once-a day fixed-dose combination regimen. 
Despite increased ART coverage, patients still die when started on ART and the threat posed 
by a higher treatment burden cannot be overlooked15, 20,31,49,50.  
Several studies have examined survival among PLWH, but very few have focused on 
young people.  In addition, little is known about the effect of the changing ART policy on 
survival of young people in Uganda. Survival rates vary by region and age, and providing 
country-specific data will help define local priorities and reduce barriers to treatment. We 
therefore evaluated the effect of the 2014 policy ART changes on survival among young 
people, aged 15-24 years, initiating ART in Uganda.   
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Methods 
Study Design and Data Source 
We conducted a retrospective cohort study using administrative data from the District 
Health Information System (DHIS2) and the national referral hospital’s EMR.  We compared 
young people who started ART in the period July 1st, 2014 to December 31st, 2016 to a 
historical cohort that was treated in January 1st, 2012 to 30th June 2014 before the policy 
change. This data, routinely collected from patients who receive HIV treatment at the ART 
clinics during routine visits, is used to track a patient’s treatment plan from the date of HIV 
diagnosis to the date he/she leaves the clinic either through transfer-out to another clinic, 
lost to follow-up (LTFU) or death.  
 
Study Cohort 
All individuals that were 15-24 years old at the time of ART initiation and on long-term 
ART, were included in the study. Patients who were LTFU or transferred-out were considered 
for the period when they were in care.  We excluded patients who were lost- to- follow-up 
before the start of the study period, started ART for Pre-exposure prophylaxis (PrEP) because 
it is short term, had no records, and had started ART elsewhere (transfer-in) for lack of 
information from the referral health facility. We also excluded patients who had no follow up 
visit after ART initiation. 
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Dependent Variables 
We defined survival as the time between ART initiation and death or end of study 
period. For more comparable results the total follow-up time for each group was restricted 
to 36 months after starting ART. For young people in the pre-policy group, the censor date 
was December 2014 and for those in the post-policy group, the censor date was June 2017. 
Length of time was measured in months. The variable was coded as “1” if the patient died 
and “0” otherwise.  
 
Independent Variables 
The independent variable of interest was a binary time variable (pre-2014 policy =0, 
post-2014 policy=1). The pre-policy group included young people who started ART before July 
2014 (January 2012 – June 2014) and the post-policy group included young people who 
started ART after July 2014 (July 2014-December 2016). The socio-demographic variables 
were ART clinic, gender and age at ART start. The clinical characteristics were weight, OI at 
ART start (Yes, No) and WHO clinical disease stage (I, II, III) at ART start. The treatment 
characteristics included duration in pre-ART care (less than 1 month, 1 month or more), ARV 
drug regimen (TDF, Non-TDF), the number of ARV pills per day (1 pill, 2 pills or more) given at 
ART start, cotrimoxazole prophylaxis at ART start (Yes, No) and ART adherence (adherent, less 
adherent) at the time of death/end of study period. 
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Analysis 
All statistical analyses were performed using STATA 15 and SAS 9.4. We described and 
compared patient characteristics using T-tests and Pearson’s chi-squared tests, respectively 
(Table 1). All p-values were two-tailed and considered statistically significant at α=0.05. To 
assess associations of each independent variable with the dependent variable, survival, 
univariable analyses were first performed.  We conducted multivariable Cox Proportional 
Hazards regression analyses to determine the effect of the change in policy on survival, 
controlling for age at the time of the event, sex, OI at ART start, ARV regimen, ARV pills per 
day given and adherence at the time of death/send of study. All variables that were 
statistically significant at p-value <0.25 or had prior clinical significance for survival from the 
univariable analysis, were included in the multivariable regression model. We checked the 
correlation between the variables to ensure that none was highly correlated. Possible 
interactions were also checked and none of them was significant. We used the log-rank test 
to test the difference in survival functions between the two groups. We checked the 
underlying model assumptions of the proportional hazards model using the model-based test 
for time by log (t) interaction. The overall model fit was assessed using Cox-Snell residuals. 
We report both unadjusted and adjusted hazard ratios and 95% confidence intervals in Table 
8. 
 
  
98 
 
IRB approval 
The study was approved by the Makerere University School of Public Health, Uganda 
National Council of Science and Technology, Baylor College of Medicine’s Institutional Review 
Board, and Committee for the Protection of Human Subjects at the University Of Texas Health 
Sciences Center at Houston.  
 
Results  
This analysis included data from 3084 young people who met the inclusion-exclusion 
criteria out of 3532. 50.13% of these started ART before and 49.87% started ART after the 
policy change. Although there were no significant group differences in age at ART start and 
gender, young people were more likely to be older (20-24 years) and female. The number of 
young people initiating ART was different between clinics, but within the clinics there was not 
much difference, pre- and post- policy. More than 76% of young people did not have an OI at 
ART initiation in both groups.  But among those who had an OI, the pre-policy group was 
bigger (23.54%) compared to 18.60% in the post-policy group. 57% pre-policy and 75% post-
policy young people started ART with stage I disease. The pre-policy group had more young 
people (32%) starting ART with stage II disease compared to post-policy group (17%).  In both 
groups, ART initiation was in less than a month of testing HIV positive. However, the post-
policy group had a bigger percentage (93%) compared to the pre-policy group (88%). A sub-
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analysis showed that among those who started ART in less than a month, nearly 50% in the 
post-group and 30% in the pre-group started ART the same day they tested positive for HIV. 
More young people in the pre-policy group (11.77%) stayed in pre-ART care more than a 
month. Post-policy young people were more likely to be given a TDF-based regimen (93%) 
and one pill a day (86%). Almost all the young people in both groups were given cotrimoxazole 
prophylaxis at ART start.  There were no group differences in the number of young people 
who died during the study period.  However, those in the post-policy group were more likely 
to be LTFU (7.11%) or to transfer-out to another facility (19.32%) compared to those in the 
pre-policy group. 
The survival probabilities of both groups were close to 1 (Figure 7). The log rank test 
(2.56) was not statistically significant (P <0.11) and there was not enough evidence to reject 
the null hypothesis that there is no difference in the survival probabilities of the two groups.  
In the both the unadjusted and adjusted models there was no significant difference 
between the hazard ratios of young people who started ART before and those who started 
ART after the policy changed (Table 8). However, whereas the risk of death was lower in the 
unadjusted model (HR: 0.58, 95%CI: 0.29, 1.15), it was three times higher in the adjusted 
model (HR: 1.55, 95%CI: 0.46, 5.28), after controlling for age at the time of death/end of study 
period, gender, weight at ART start, OI at ART start, WHO disease stage at ART start, duration 
in pre-ART care, number of ARV pills per day and ART adherence at the time of death/end of 
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study period. Only weight at ART start, WHO disease stage and ART adherence at the time of 
death/end of study period had a significant effect of survival in the adjusted regression 
model. Young people who had stage II, III&IV at ART start had more than three times the risk 
of death (HR 3.88, 95%CI 1.01, 14.99 and 8.63, 95%CI: 2.48, 29.98, respectively) compared to 
those who had stage I at ART start. But the 95% CIs were wide. Those who were less adherent 
had lower odds of survival compared to those who were adherent.  The difference was 
statistically significant. 
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Table 7: Descriptive Statistics of Young People who started ART before and after the 
Policy Change 
Characteristic Pre-2014 policy  Post-2014 policy 
Total  1546 1538 
Dependent Variable   
Deaths    
Yes 1.42% 0.85% 
No 98.58% 99.15%  
   
Independent Variables   
Policy change group   
Pre-Policy 50.13%   
Post- Policy  49.87%  
Year of ART initiation    
2012 (reference) 28.78%   
2013 47.54%   
2014 23.67%  27.57%  
2015  36.74%  
2016  35.70%  
Socio-Demographic Characteristics   
Age at ART start in years (%)   
15-19 28.91% 28.67% 
20-24  71.09% 71.33% 
Gender (%)   
Male  14.81% 13.72% 
Female 85.19%  86.23%  
   
Weight at ART start in kgs (mean, SD) 55.26(10.15)  55.45(9.30)  
   
Health Facility (%)   
ART clinic 1   15.46% * 16.64% * 
ART clinic 2 39.72% * 31.99% * 
ART clinic 3 10.93% * 10.14% * 
ART clinic 4  33.89% * 41.22% * 
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Characteristic Pre-2014 policy  Post-2014 policy 
Total  1546 1538 
Clinical Characteristics   
Had an OI at ART Start (%)   
Yes 23.54% * 18.60% * 
No  76.46% * 81.40% * 
WHO disease stage at ART start (%)   
Stage I  57.32% * 75.36%* 
Stage II 32.25% * 17.30% * 
Stage III & IV 10.43% * 7.34% * 
Treatment Characteristics   
Duration in Pre –ART care in months (%)   
<1 month 88.23% * 93.17% * 
1 month + 11.77% * 6.38% * 
ARV regimen given at ART start (%)   
TDF 65.65% * 92.59% * 
Non-TDF 34.35% * 7.41% * 
ARV pills per day at ART start (%)   
1 pill 45.34% * 85.57% * 
2 pills or more 54.66% * 14.43% * 
Cotrimoxazole Prophylaxis at ART start (%)   
Yes 97.67% * 99.09% * 
No (reference) 2.33% * 0.91% * 
Lost to Follow-up   
Yes 2.72* 7.22* 
No 97.28* 92.78* 
Transfer-Out   
Yes 8.02* 19.25* 
No 91.98* 80.75* 
Age at time of death/censor   
15-19 83.89% *  87.26% * 
20-24  16.11% * 12.74% *  
ART Adherence at time of death/censor   
Adherent 71.82%  71.05%  
Less Adherent 28.18%  28.95%  
*Significant at P<0.05   
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Figure 6: Trends in Deaths among Young People before and after the Policy Change 
 
 
 
Figure 7: Comparison of Survival Probabilities of Young People before and after the 2014 
ART Policy 
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Table 8: The Effect of the Independent Variables on Survival among HIV Positive Young 
People, Before and After the 2014 ART Policy Change 
Characteristic Unadjusted HR (95% CI) Adjusted HR (95% CI) 
Pre/Post Group   
Pre-2014 policy Reference Reference 
Post-2014 policy 0.58 (0.29, 1.15) 1.55 (0.46, 5.28) 
Patient socio-demographic characteristics   
Age at time of time of death/censor   
15-19 years 1.84 (0.83, 4.08) 1.45 (0.49, 4.26) 
20-24 years Reference Reference  
Gender   
Male 3.13 (1.56, 6.31) ** 1.15 (0.36, 3.60) 
Female Reference Reference 
Patient Clinical Characteristics   
Weight at ART start 0.91 (0.89, 0.93) ** 0.93 (0.89, 0.97) ** 
Had an OI at ART start   
Yes 3.12 (1.60, 6.07) ** 0.97 ((0.40, 2.33) 
No Reference Reference 
WHO disease stage at ART start   
Stage I Reference Reference 
Stage II 3.53 (1.23, 10.14) * 3.88 (1.01, 14.99) * 
Stage III & IV 23.56 (9.48, 58.67) **  8.63 (2.48, 29.98) ** 
Patient Treatment Characteristics   
Duration in PreART care   
< 1 month Reference  Reference  
One Month or more 0.30 (0.04, 2.14) 0.60 (0.08, 4.37) 
ARV pills per day at ART start   
1 pill 0.36 (0.19, 0.71) ** 0.41 (0.11, 1.47) 
2 pills or more Reference Reference 
Adherence at the time of death/censor   
Adherent Reference  Reference  
Less adherent 0.46 (0.16, 1.32) 0.26 (0.09, 0.80) * 
*Significant at P<0.05 
**Significant at P<0.01 
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Discussion 
In this study we found that young people had higher survival probabilities after ART 
initiation regardless of whether they started ART before or after the policy change (Figure 7). 
Less than 2% (0.54 per 1000 person-months) died during the follow-up period which was 
lower than the 6.2 per 100 person years reported in a similar study done in Uganda59. Our 
sample had a very small number of deaths. The low number of deaths could be attributed to 
the increased ART coverage in the country that is prolonging the life of PLWHA given the 
strong and consistent evidence that ART improves survival23,24.  
This study did not find a significant association between the policy change group and 
survival of young people. With the small number of deaths in our sample, we may not have 
had an adequate number of deaths to detect a difference between the groups. Although the 
result was not significant, it was surprising that the risk of death increased in the post-policy 
group in the adjusted model. Whereas in the unadjusted model, the post-policy group had a 
lower hazard rate (HR: 0.58, 95%CI: 0.29, 1.15) compared to the pre-policy group, this 
changed (HR: 1.55, 95%CI: 0.46, 5.28) in favor of the pre-policy group in the adjusted model. 
It should also be noted that a bigger number of young people in the post-policy group had 
disease stage I at ART start and started ART in less than a month of being diagnosed. 
Therefore, there may by other factors driving this increased risk that need further research. 
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In addition, our study was limited by the lack of death registry data and a centralized 
database for PLWHA. There are unreported deaths in the community in general and also 
among young people who are lost or were transferred-out to other ART clinics for treatment. 
Therefore, this study could have underestimated death and overestimated survival.  
It is evident in published literature that disease severity significantly increases the risk 
of death61 among PLWH. Our study found that young people with disease stage II, III & IV at 
ART start had a significant effect on survival (HR 3.88, 95%CI 1.01, 14.99 and 8.63, 95%CI: 
2.48, 29.98, respectively). Young people had more than three times the risk of death and 
nearly nine times higher risk compared to those with stage I at ART start, during the 36 
months of follow-up. Other studies done in Africa have reported similar results that OIs and 
the Immune Reconstitution Inflammatory Syndrome (IRIS) were major causes of death after 
initiation of ART61,62.  Our results could be attributed to the number of young people in our 
sample who had disease stage III and IV at the start of treatment. Overall nearly 40% of the 
young people had disease stage II, III & IV at ART start.  In addition, 23% of that young people 
in the pre-policy group and 18% in the post-policy group had an OI at the start of ART. It 
should also be noted that although the prevalence of OIs is not as high as before the ART era, 
they still exist and there are some that still persist50,52 . Therefore, their impact on survival 
cannot be overlooked or underestimated. 
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Our study also found that ART adherence at the time of death/study period had a 
significant effect on survival. It was surprising that less adherent young people had a lower 
hazard ratio compared to the adherent young people (HR:0.26, 95%CI: 0.09, 0.80). This was 
contrary to what we expected to find and what has been reported in published literature. 
Several studies have found that less adherent patients had a higher risk of death compared 
to adherent patients. Studies in Ethiopia, found that the risk of death was nearly 3 times 
higher (HR: 2.9695, 95% CI: 1.396 – 5.203) among patients with poor adherence63. In Uganda 
it has been reported that non-adherent patients were 2 times more likely to die compared to 
adherent patients64.  Therefore, given that unexpected results, the existing literature, and the 
low number of deaths in the study sample, more investigation is needed into the survival of 
young people starting ART in the post policy era. 
Among the strengths of this study is that this is the first study to evaluate the effect 
of the changes in ART policy on survival among young people in Uganda. This study had a 
large study cohort of young people from 4 large volume HIV clinics that are representative of 
the 4 geographical regions in Uganda. The regional variation increases generalizability of the 
study results.  Our study also had some limitations.  Our study may have misclassified the 
number of young people who were LTFU and transferred out as dead due to lack of tracking 
such patients. Adolescents who were perinatally infected with HIV may have introduced some 
survival bias in our analysis. Also common in such studies, some unobserved measures may 
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exist and could have affected our findings. However, our findings are unlikely to differ from 
other ART clinics in Uganda. 
 
Conclusion 
In conclusion therefore, young people are likely to survive longer after ART initiation 
regardless of whether they started ART before or after the policy changed.  However, given 
that the risk of death among the post-policy group was higher and ART adherence had an 
effect on survival, more investigation is needed to identify factors that may be influencing 
this.   
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CONCLUSION 
This study found that ART adherence among young people was mainly driven by 
differences between health facilities providing ART in Uganda and whether an individual had 
an OI at ART start and not by policy change. Also, ART adherence declined over time. This 
study also found that the risk of OIs was lower among young who initiated ART after the policy 
change. Furthermore, young people are more likely to survive longer after ART initiation 
regardless of whether they started ART before or after the policy changed.  Therefore, 
whereas initiating treatment before onset of advanced disease is beneficial to reducing HIV-
related morbidity and mortality, the implications on long term adherence cannot be 
overlooked. Given our findings, we believe that there are factors influencing ART adherence, 
OIs and survival among young people that are not captured by our study, that need further 
investigation. 
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APPENDICES  
Appendix 1: Data extraction tool 
Qn. Description  
 Information Response  
1.  Name of Health Facility 
1=ART Clinic 1; 2= ART Clinic 2; 3 = ART Clinic 3; 4= 
ART Clinic 4 
2.  Patient Name 
Will only be used for data extraction and cleaning. 
A unique study ID will be generated for analysis 
3.  Patient Clinic Number 
Will only be used for data extraction and cleaning. 
A unique study ID will be generated for analysis 
4.  Patient Study ID This is the ID that will be used in the analysis 
 Demographic and Baseline Information  
5.  Sex  0=Male 1=Female 
6.  Date of Birth dd/mm/yyyy 
7.  Age In years 
8.  
Date Patient started treatment at this 
health facility 
dd/mm/yyyy 
9.  Date patient was diagnosed with HIV dd/mm/yyyy 
10.  ART start date  dd/mm/yyyy 
11.  ART regimen at ART start  
12.  
Number of pills in a daily dose at ART 
start 
 
13.  Weight at ART start in kilograms 
14.  WHO clinic disease stage at ART start 1=Stage 1; 2=Stage 2; 3=Stage 3; 4=Stage 4 
15.  TB status at ART start 1=No signs; 2=suspect; 3 =TB Rx 
16.  New/Other OIs at ART start 1 =Yes, 0=No 
17.  Name of new/other OIs at ART start  
18.  CD4 cell count at ART start Cells/mm3 
19.  Pre-ART Opportunistic Infection (OI)  1 =Yes, 0=No 
20.  Cotrimoxazole (CPT) dose at ART start 1 =Yes, 0=No 
21.  Duration in Pre-ART care In months 
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 Followup information – Repeat for every visit for the specified study duration 
22.  Visit date dd/mm/yyyy 
23.  Follow-up date dd/mm/yyyy 
24.  TB status 1=No signs; 2=suspect; 3 =TB Rx 
25.  New/Other OIs at ART start 1 =Yes, 0=No 
26.  Name of new/other OIs   
27.  WHO clinical disease stage 1=Stage 1; 2=Stage 2; 3=Stage 3; 4=Stage 4 
28.  ARV adherence score 1=Adherent (≥ 95%), 0=Less Adherent (<95%) 
29.  Transfer out date dd/mm/yyyy 
30.  Loss to follow up date dd/mm/yyyy 
31.  Date patient died dd/mm/yyyy 
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Appendix 2: Research Approval – UTHealth 
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Appendix 3: Research Approval – Baylor College of Medicine 
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Appendix 4: Research Approval – UNCST 
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Appendix 5: Human Subjects Certification – CITI certificate 
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